<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3107222366
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMNOVID 3 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        POMALIDOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29031.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CELGENE INTERNATIONAL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CELGENE INTERNATIONAL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Bristol-Myers Squibb / Pharma EEIG 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AX06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Imnovid is</p><p>Imnovid contains the active substance &lsquo;pomalidomide&rsquo;. This medicine is related to thalidomide and belongs to a group of medicines which affect the immune system (the body&rsquo;s natural defences).</p><p>What Imnovid is used for</p><p>Imnovid is used to treat adults with a type of cancer called &lsquo;multiple myeloma&rsquo;.</p><p>Imnovid is either used with:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>two other medicines </strong>- called &lsquo;bortezomib&rsquo; (a type of chemotherapy medicine) and &lsquo;dexamethasone&rsquo; (an anti-inflammatory medicine) in people who have had at least one other treatment - including lenalidomide.</p><p>Or</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>one other medicine </strong>- called &lsquo;dexamethasone&rsquo; in people whose myeloma has become worse, despite having at least two other treatments - including lenalidomide and bortezomib.</p><p>What is multiple myeloma</p><p>Multiple myeloma is a type of cancer which affects a certain type of white blood cell (called the &lsquo;plasma cell&rsquo;). These cells grow out of control and accumulate in the bone marrow. This results in damage to the bones and kidneys.</p><p>Multiple myeloma generally cannot be cured. However, treatment can reduce the signs and symptoms of the disease, or make them disappear for a period of time. When this happens, it is called &lsquo;response&rsquo;.</p><p>How Imnovid works</p><p>Imnovid works in a number of different ways:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stopping the myeloma cells developing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stimulating the immune system to attack the cancer cells</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by stopping the formation of blood vessels supplying the cancer cells.</p><p>The benefit of using Imnovid with bortezomib and dexamethasone</p><p>When Imnovid is used with bortezomib and dexamethasone, in people who have had at least one other treatment, it can stop multiple myeloma getting worse:</p><p>&nbsp;&nbsp; On average, Imnovid when used with bortezomib and dexamethasone stopped multiple myeloma from coming back for up to 11 months - compared with 7 months for those patients who only used bortezomib and dexamethasone.</p><p>The benefit of using Imnovid with dexamethasone</p><p>When Imnovid is used with dexamethasone, in people who have had at least two other treatments, it can stop multiple myeloma getting worse:</p><p>&nbsp;&nbsp;&nbsp; On average, Imnovid when used with dexamethasone stopped multiple myeloma from coming back for up to 4 months compared with 2 months for those patients who used only dexamethasone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You will have been given specific instructions by your doctor, particularly on the effects of Imnovid on unborn babies (outlined in the <em>i-SECURE </em>program).</p><p>You will have been given an Imnovid <em>i-SECURE </em>Patient Brochure by your doctor. Read it carefully and follow the related instructions.</p><p>If you do not fully understand these instructions, please ask your doctor to explain them again <strong>before you take Imnovid</strong>. See also further information in this section under &ldquo;Pregnancy, contraception and breastfeeding&rdquo;.</p><p><strong>Do not take Imnovid:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or think you may be pregnant or are planning to become pregnant &ndash; this is because <strong>Imnovid is expected to be harmful to an unborn child</strong>. (Men and women taking this medicine must read the section &ldquo;Pregnancy, contraception and breast-feeding &ndash; information for women and men&rdquo; below).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are able to become pregnant, unless you follow all the necessary measures to prevent you from becoming pregnant (see &ldquo;Pregnancy, contraception and breast-feeding &ndash; information for women and men&rdquo;). If you are able to become pregnant, your doctor will record with each prescription that the necessary measures have been taken and will provide you with this confirmation.</p><p>if you are allergic to pomalidomide or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.</p><p>If you are uncertain whether any of the conditions above apply to you, talk to your doctor, pharmacist or nurse before taking Imnovid.</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before taking Imnovid if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had blood clots in the past. During the treatment with Imnovid you have an increased risk of getting blood clots in your veins and arteries. Your doctor may recommend you take additional treatments (e.g. warfarin) or lower the dose of Imnovid to reduce the chance that you get blood clots.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had an allergic reaction such as rash, itching, swelling, feeling dizzy or trouble breathing while taking related medicines called &lsquo;thalidomide&rsquo; or &lsquo;lenalidomide&rsquo;.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had a heart attack, have heart failure, have difficulty breathing, or if you smoke, have high blood pressure or high cholesterol levels.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the blood which can lead to kidney failure. You may also experience an uneven heartbeat. This condition is called tumour lysis syndrome.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had neuropathy (nerve damage causing tingling or pain in your hands or feet).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have ever had hepatitis B infection. Treatment with Imnovid may cause the hepatitis B virus to become active again in patients who carry the virus, resulting in a recurrence of the infection. Your doctor should check whether you have ever had hepatitis B infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you experience or have experienced in the past a combination of any of the following symptoms:</p><p>rash on face or extended rash, red skin, high fever, flu-like symptoms, enlarged lymph nodes (signs of severe skin reaction called Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) or drug hypersensitivity syndrome, Toxic Epidermal Necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). See also section 4 &ldquo;Possible side effects&rdquo;).</p><p>It is important to note that patients with multiple myeloma treated with pomalidomide may develop additional types of cancer, therefore your doctor should carefully evaluate the benefit and risk when you are prescribed this medicine.</p><p>At any time during or after your treatment, tell your doctor or nurse immediately if you:</p><p>experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you had these symptoms prior to treatment with Imnovid, tell your doctor about any change in these symptoms.</p><p>Pregnancy, contraception and breast-feeding &ndash; information for women and men</p><p>The following must be followed as stated in the Pomalidomide <em>i-SECURE </em>Pregnancy Prevention Programme.</p><p>Women and men taking Imnovid must not become pregnant or father a child. This is because pomalidomide is expected to harm the unborn baby. You and your partner should use effective methods of contraception while taking this medicine.</p><p>Women</p><p>Do not take Imnovid if you are pregnant, think you may be pregnant or are planning to become pregnant. This is because this medicine is expected to harm the unborn baby. Before starting the treatment, you should tell your doctor if you are able to become pregnant, even if you think this is unlikely.</p><p>If you are able to become pregnant:</p><p>&nbsp;</p><p>you must use effective methods of contraception for at least 4 weeks before starting treatment, for the whole time you are taking treatment, and until at least 4 weeks after stopping treatment. Talk to your doctor about the best method of contraception for you.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; each time your doctor writes a prescription for you, he will ensure you understand the necessary measures that have to be taken to prevent pregnancy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will arrange pregnancy tests before treatment, at least every 4 weeks during treatment, and at least 4 weeks after the treatment has finished</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Breast-feeding</em></p><p>It is not known if Imnovid passes into human breast milk. Tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will advise if you should stop or continue breast-feeding.</p><p>Men</p><p>Imnovid passes into human semen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your partner is pregnant or able to become pregnant, you must use condoms for the whole time you are taking treatment and for 7 days after the end of treatment.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your partner becomes pregnant while you are taking Imnovid, tell your doctor straight away. Your partner should also tell her doctor straight away.</p><p>You should not donate semen or sperm during treatment and for 7 days after the end of treatment.</p><p>Blood donation and blood tests</p><p>You should not donate blood during treatment and for 7 days after the end of treatment.</p><p>Before and during the treatment with Imnovid you will have regular blood tests. This is because your medicine may cause a fall in the number of blood cells that help fight infection (white cells) and in the number of cells that help to stop bleeding (platelets).</p><p>Your doctor should ask you to have a blood test: &nbsp;&nbsp;&nbsp;&nbsp; before treatment</p><p>every week for the first 8 weeks of treatment</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at least every month after that for as long as you are taking Imnovid.</p><p>As a result of these tests, your doctor may change your dose of Imnovid or stop your treatment. The doctor may also change the dose or stop the medicine because of your general health.</p><p><strong>Children and adolescents </strong></p><p>Imnovid is not recommended for use in children and young people under 18 years.</p><p>Other medicines and Imnovid</p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Imnovid can affect the way some other medicines work. Also some other medicines can affect the way Imnovid works.</p><p>In particular, tell your doctor, pharmacist or nurse before taking Imnovid if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antifungals such as ketaconazole</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some antibiotics (for example ciprofloxacin, enoxacin) &nbsp;&nbsp; certain antidepressants such as fluvoxamine.</p><p>Driving and using machines</p><p>Some people feel tired, dizzy, faint, confused or less alert when taking Imnovid. If this happens to you, do not drive or operate tools or machinery.</p><p>Imnovid contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, therefore it is considered essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Imnovid must be given to you by a doctor with experience in treating multiple myeloma.</p><p>Always take your medicines exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>When to take Imnovid with other medicines</p><p>Imnovid with bortezomib and dexamethasone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See the leaflets that come with bortezomib and dexamethasone for further information on their use and effects.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imnovid, bortezomib and dexamethasone are taken in &lsquo;treatment cycles&rsquo;. Each cycle lasts 21 days (3 weeks).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look at the chart below to see what to take on each day of the 3-week cycle:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each day, look down the chart and find the correct day to see which medicines to take.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some days, you take all 3 medicines, some days just 2 or 1 medicines, and some days none at all.</p><p><strong>IMN: </strong>Imnovid; <strong>BOR</strong>: Bortezomib; <strong>DEX</strong>: Dexamethasone</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 1 to 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cycle 9 and onwards</p><table border="0" cellspacing="0" cellpadding="0" style="width:583px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Medicine name</strong></p></td><td rowspan="23" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Medicine name</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>BOR</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>BOR</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After completing each 3-week cycle, start a new one.</p><p>Imnovid with dexamethasone only</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See the leaflet that comes with dexamethasone for further information on its use and effects.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imnovid and dexamethasone are taken in &lsquo;treatment cycles&rsquo;. Each cycle lasts 28 days (4 weeks).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Look at the chart below to see what to take on each day of the 4-week cycle:</p><p>o Each day, look down the chart and find the correct day to see which medicines to take. o&nbsp; Some days, you take both medicines, some days just 1 medicine, and some days none at all.</p><p><strong>IMN: </strong>Imnovid; <strong>DEX</strong>: Dexamethasone</p><table border="0" cellspacing="0" cellpadding="0" style="width:177px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Medicine name</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Day</strong></p></td><td style="vertical-align:top"><p><strong>IMN</strong></p></td><td style="vertical-align:top"><p><strong>DEX</strong></p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:177px"><tbody><tr><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td></tr><tr><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After completing each 4-week cycle, start a new one.</p><p>How much Imnovid to take with other medicines</p><p>Imnovid with bortezomib and dexamethasone</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of Imnovid is 4 mg per day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of bortezomib will be worked out by your doctor and based on your height and weight (1.3 mg/m<sup>2 </sup>body surface area).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of dexamethasone is 20 mg per day. However, if you are over 75, the recommended starting dose is 10 mg per day.</p><p>Imnovid with dexamethasone only</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose of Imnovid is 4 mg per day.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended starting dose of dexamethasone is 40 mg per day. However, if you are over 75, the recommended starting dose is 20 mg per day.</p><p>Your doctor may need to reduce the dose of Imnovid, bortezomib or dexamethasone or stop one or more of these medicines based on the results of your blood tests, your general condition, other medicines you may be taking (e.g. ciprofloxacin, enoxacin and fluvoxamine) and if you experience side effects (especially rash or swelling) from treatment.</p><p>If you suffer from liver or kidney problems your doctor will check your condition very carefully whilst you are receiving this medicine.</p><p>How to take Imnovid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not break, open or chew the capsules. If powder from a broken Imnovid capsule makes contact with the skin, wash the skin immediately and thoroughly with soap and water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the capsules whole, preferably with water.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take the capsules either with or without food.</p><p>Take Imnovid at about the same time each day.</p><p>To remove the capsule from the blister, press only one end of the capsule out to push it through the foil. Do not apply pressure on the centre of the capsule as this can cause it to break.</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p>Your doctor will advise you of how and when to take Imnovid if you have kidney problems and are receiving dialysis treatment.</p><p><strong>Duration of the treatment with Imnovid</strong></p><p>You should continue the cycles of treatment until your doctor tells you to stop.</p><p>If you take more Imnovid than you should</p><p>If you take more Imnovid than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p>If you forget to take Imnovid</p><p>If you forget to take Imnovid on a day when you should, take your next capsule as normal the next day. Do not increase the number of capsules you take to make up for not taking Imnovid the previous day.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects</p><p><strong>Stop taking Imnovid and see a doctor straight away if you notice any of the following serious side effects &ndash; you may need urgent medical treatment:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever, chills, sore throat, cough, mouth ulcers or any other signs of infection (due to less white blood cells, which fight infection).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding or bruising without a cause, including nosebleeds and bleeding from the bowels or stomach (due to effects on blood cells called &lsquo;platelets&rsquo;).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rapid breathing, rapid pulse, fever and chills, passing very little to no urine, nausea and vomiting, confusion, unconsciousness (due to infection of blood called sepsis or septic shock).</p><p>Severe, persistent or bloody diarrhoea (possibly with stomach pain or fever) caused by bacteria called <em>Clostridium difficile</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, or leg pain and swelling, especially in your lower leg or calves (caused by blood clots).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (from serious chest infection, inflammation of the lung, heart failure or blood clot).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of face, lips, tongue and throat, which may cause difficulty breathing (due to a serious type of allergic reaction called angioedema).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of skin cancer (squamous cell carcinoma and basal cell carcinoma), which can cause changes in the appearance of your skin or growths on your skin. If you notice any changes to your skin whilst taking Imnovid, tell your doctor as soon as possible.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recurrence of hepatitis B infection, which can cause yellowing of the skin and eyes, dark browncoloured urine, right-sided abdominal pain, fever and feeling nauseous or being sick. Tell your doctor straightaway if you notice any of these symptoms.</p><p><strong>Stop taking Imnovid and see a doctor straight away </strong>if you notice any of the serious side effects listed above &ndash; you may need urgent medical treatment.</p><p>Other side effects</p><p><strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath (dyspnoea).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the lungs (pneumonia and bronchitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the nose, sinuses and throat, caused by bacteria or viruses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low red blood cells, which may cause anaemia leading to tiredness and weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of potassium (hypokalaemia), which may cause weakness, muscle cramps, muscle aches, palpitations, tingling or numbness, dyspnoea, mood changes. &nbsp;&nbsp; High blood levels of sugar.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, diarrhoea or nausea. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of energy.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in falling asleep or staying asleep.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, tremor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle spasm, muscle weakness. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone pain, back pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, tingling or burning sensation to the skin, pains in hands or feet (peripheral sensory neuropathy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the body, including swelling of the arms or legs.</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fall.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding within the skull.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased ability to move or feel (sensation) in your hands, arms, feet and legs because of nerve damage (peripheral sensorimotor neuropathy).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Numbness, itching, and a feeling of pins and needles on your skin (paraesthesia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A spinning feeling in your head, making it difficult to stand up and move normally.</p><p>Swelling caused by fluid.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives (urticaria).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rashes.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy skin. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fast and irregular heartbeat (atrial fibrillation).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart attack (chest pain spreading to the arms, neck, jaw, feeling sweaty and breathless, feeling sick or vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, chest infection. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A fall in the number of red and white blood cells and platelets at the same time (pancytopenia), which will make you more prone to bleeding and bruising. You may feel tired and weak, and short of breath and you are also more likely to get infections.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased number of lymphocytes (one type of white blood cells) often caused by infection (lymphopenia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of magnesium (hypomagnesaemia), which may cause tiredness, generalised weakness, muscle cramps, irritability and may result in low blood levels of calcium (hypocalcaemia), which may cause numbness and, or tingling of hands, feet, or lips, muscle cramps, muscle weakness, light-headedness, confusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood level of phosphate (hypophosphataemia), which may cause muscle weakness and irritability or confusion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood level of calcium (hypercalcaemia), which may cause slowing reflexes and skeletal muscle weaknesses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood levels of potassium, which may cause abnormal heart rhythm.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood levels of sodium, which may cause tiredness and confusion, muscle twitching, fits (epileptic seizures) or coma.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood levels of uric acid, which may cause a form of arthritis called gout. &nbsp;&nbsp; Low blood pressure, which may cause dizziness or fainting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms (influenza).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore or dry mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way things taste.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain, swollen abdomen.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling confused.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling down (depressed mood).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of consciousness, fainting.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clouding of your eye (cataract).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the kidney.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to pass urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver test.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection, which may cause a burning sensation when passing urine, or a need to pass urine more often.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the pelvis. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the liver (hepatitis) which can cause itchy skin, yellowing of the skin and the whites of the eyes (jaundice), pale coloured stools, dark coloured urine and abdominal pain.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The breakdown of cancer cells resulting in the release of toxic compounds into the bloodstream (tumour lysis syndrome). This can result in kidney problems.</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Widespread rash, high body temperature, enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome, Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome). Stop using pomalidomide if you develop these symptoms and contact your doctor or seek medical attention immediately. See also section 2.</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30<sup>o</sup>C.</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not use Imnovid if you notice any damage or signs of tampering to medicine packaging.</p><p>Do not throw away any medicines via wastewater or household waste. Any unused medicine should be returned to the pharmacist at the end of treatment. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol (E421), starch, pregelatinised, and sodium stearyl fumarate.</p><p>Imnovid 1 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 1 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132) and yellow iron oxide (E172) and white and black ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527) (white ink) and shellac, iron oxide black (E172), propylene glycol (E1520) and ammonium hydroxide (E527) (black ink).</p><p>Imnovid 2 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 2 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172), erythrosin (E127) and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p><p>Imnovid 3 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 3 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), yellow iron oxide (E172) and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p><p>Imnovid 4 mg hard capsule:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each capsule contains 4 mg of pomalidomide.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The capsule shell contains: gelatin, titanium dioxide (E171), indigotine (E132), brilliant blue FCF (E133), and white ink.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The printing ink contains: white ink - shellac, titanium dioxide (E171), simeticone, propylene glycol (E1520) and ammonium hydroxide (E527).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imnovid 1 mg hard capsules: Dark blue opaque cap and yellow opaque body, with “POML 1 mg” written on them.
Imnovid 2 mg hard capsules: Dark blue opaque cap and orange opaque body, with “POML 2 mg” written on them.
Imnovid 3 mg hard capsules: Dark blue opaque cap and green opaque body, with “POML 3 mg” written on them.
Imnovid 4 mg hard capsules: Dark blue opaque cap and blue opaque body, with “POML 4 mg” written on them.
Each pack contains 21 capsules: (3 blisters x 7 capsules)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>Bristol-Myers Squibb Pharma EEIG&nbsp;</p><p>Plaza 254</p><p>Blanchardstown Corporate Park 2</p><p>Dublin 15, D15 T867</p><p>Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in August 2021 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو&nbsp;إمنوفيد</strong></p><p dir="RTL">يحتوي إمنوفيد على المادة الفعالة&#39; بوماليدومايد&#39;. هذا الدواء هو ذو صلة بالثاليدومایيد وينتمي إلى مجموعة من الأدوية&nbsp;التي تؤثر على الجهاز المناعي (الدفاعات الطبیعیة في الجسم).&nbsp;&nbsp;</p><p dir="RTL"><strong>ما ھي دواعي استعمال إمنوفيد</strong></p><p>&nbsp;</p><p dir="RTL">يستعمل إمنوفيد لعلاج البالغين الذين يعانون من نوع من السرطان يسمى&#39;الورم النقوي المتعدد&#39;.</p><p dir="RTL">إمنوفيد يستخدم إما مع:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواءان آخران - ُيدُعى &quot;بورتيزوميب&quot; (نوع من دواء العلاج الكيميائي) و &quot;ديكساميثازون&quot; (دواء مضاد للالتهابات) في الأشخاص الذين تلقوا علاًجًا واحدًا آخر على الأقل - بما في ذلك الليناليدوميد.</p><p dir="RTL">أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء آخر&nbsp; - يسمى &quot;ديكساميثازون&quot; من قبل الأشخاص الذين أصبح عندهم الورم النقوي أسوأ، على الرغم من تناولهم على الأقل نوعين من أنواع العلاجات الأخرى، بما في ذلك ليناليدومايد و بورتيزوميب.</p><p dir="RTL"><strong>ما ھو الورم النقوي المتعدد</strong>&nbsp;</p><p dir="RTL">الورم النقوي المتعدد ھو نوع من أنواع السرطان الذي يؤثر على نوع معين من خلايا الدم البيضاء (تسمى &#39;خلية البلازما&#39;).</p><p dir="RTL">ھذه الخلایا تنمو خارج نطاق السیطرة و تتراكم في نخاع العظام. وینتج عن ھذا أضرار في العظام و الكليتين.&nbsp;</p><p dir="RTL">وعمومااً، فإنھ لا یمكن علاج الورم النقوي المتعدد. ومع ذلك، یمكن العلاج أن یقلل من علامات وأعراض المرض، أو جعلھا تختفي لفترة من الزمن. وعندما یحدث ھذا، فإنھ یسمى &#39;الإستجابة&#39;.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>كيف يعمل إمنوفيد</strong>&nbsp;</p><p dir="RTL">إمنوفيد يعمل في عدد من الطرق المختلفة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال وقف نمو خلایا الورم النقوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال تحفيز الجهاز المناعي لمهاجمة الخلایا السرطانية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من خلال وقف تشكيل الأوعیة الدمویة التي تغذي الخلایا السرطانية.</p><table border="0" cellspacing="0" cellpadding="0" style="width:610px"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">فائدة استخدام إمنوفيد مع بورتيزوميب ودیكسامیثازون&nbsp;</p><p dir="RTL">عند استخدام إمنوفید مع بورتیزومیب و دیكسامیثازون، عند الأشخاص الذین خضعوا لعلاج واحد على الأقل یمكن أن یوقف الورم النقوي المتعدد من أن یزداد سوءاً:&nbsp;</p><p dir="RTL">&bull;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group
   id="Group_x0020_73475" o:spid="_x0000_s1028" style='width:3.35pt;height:14.15pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:shape id="Shape_x0020_197695" o:spid="_x0000_s1029" style='position:absolute;
    width:42672;height:179832;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAdT47qxAAAAN8AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9ba8Iw
FH4X/A/hCHvTdBvTWY0yBsIGImgLez02pxeWnHRNpt1+vREEHz+++3LdWyNO1PnGsYLHSQKCuHC6
4UpBnm3GryB8QNZoHJOCP/KwXg0HS0y1O/OeTodQiRjCPkUFdQhtKqUvarLoJ64ljlzpOoshwq6S
usNzDLdGPiXJVFpsODbU2NJ7TcX34dcqqL6On/9b2pln6XibbUyZZz+lUg+j/m0BIlAf7uKb+0PH
+fPZdP4C1z8RgFxdAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAB1PjurEAAAA3wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
    strokeweight="0">
    <v:stroke miterlimit="83231f" joinstyle="miter"/>
    <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
   </v:shape><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="4" height="19" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:3.35pt;
   height:14.15pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]-->بالمعدل، عند إستعمال إمنوفید مع بورتیزومیب ودیكسامیثازون فإنھ أوقف عودة الورم النقوي المتعدد لمدة تصل إلى 11شھًرًا&nbsp; مقارنةمقارنةً بـ 7 أشھر لأولئك المرضى الذین إستعملوا بورتیزومیب ودیكسامیثازون فقط.</p></td></tr></tbody></table><p dir="RTL">فائدة استخدام إمنوفید مع دیكسامیثازون&nbsp;</p><p dir="RTL">عندما یستخدم إمنوفید مع دیكسامیثازون، <!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_73885" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_197819" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="5" height="18" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->لدى الأشخاص الذین تلقوا علاجین آخرین على الأقل ، فإنھ یمكن أن یوقف الورم النقوي المتعدد من أن یزداد سوءاً:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المتوسط، عند إستعمال إمنوفید مع دیكسامیثازون فإنھ أوقف عودة الورم النقوي المتعدد لمدة تصل إلى 4أشھر مقارنة مع شھرین لأولئك المرضى الذین إستعملوا دیكسامیثازون فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سیكون قد أعطیت لك تعلیمات محددة من قبل الطبیب، وخاصة عن تأثیرات إمنوفید على الأطفال الذین لم یولدوا بعد (الواردة في برنامج <em>i-SECURE</em>).</p><p dir="RTL">وسیكون قد تم إعطاؤك كتیب إمنوفید <em>i-SECURE</em> الخاص بالمریض من قبل الطبیب. إقرأه بعنایة وإتبع الإرشادات ذات الصلة.&nbsp;</p><p dir="RTL">إذا كانت التعلیمات غیر مفھومة لك بشكل تام، الرجاء أن تطلب من طبیبك أن&nbsp; یشرحھا لك مرة أخرى قبل أن تتناول إمنوفید. شاھد أیضا مزیداً من المعلومات في ھذا القسم تحت عنوان &quot;الحمل ومنع الحمل والرضاعة الطبیعیة.&quot;&nbsp;</p><p dir="RTL"><strong>لا تتناولي إمنوفید</strong>:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حامًلاً أو تعتقدي بأنك قد تكوني حامًلاً أوتخططي لتصبحي حامًلاً -<strong> ذلك لأنھ من المتوقع أن یكون إمنوفید ضارااً للطفل الذي لم یولد بعد</strong>. (یجب على الرجال والنساء الذین یتناولون ھذا الدواء قراءة قسم &quot;الحمل ومنع الحمل والرضاعة الطبیعیة - معلومات للنساء والرجال&quot; أدناه.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قادرة على أن تصبحي حاملاحاملاً، إلا إذا كنت تتبعي جمیع التدابیر اللازمة لمنعك من الحمل(&nbsp; الإطلاع على</p><p dir="RTL">&quot;الحمل ومنع الحمل والرضاعة الطبیعیة&nbsp; - معلومات للنساء والرجال&quot;). إذا كنت قادرة على أن تصبحي حامًلاً، فإن طبیبك سوف یسجل مع كل وصفة طبیة أن التدابیر اللازمة قد تم إتخاذھا<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_73780" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAPAkFuokCAADfBgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzMVW1P2zAQ/j5p/8HKd0haXloqChIw
+mXaKsp+wOE4TTTHsWw3pP9+54udFDYQ2r6sleKL7+65tyf25XVXS9YKY6tGLZPJcZYwoXiTV2q7
TH483h/NE2YdqBxko8Qy2QubXF99/nQJi60BXVacIYKyC1gmpXN6kaaWl6IGe9xooVBXNKYGh69m
m+YGnhG5luk0y87TGiqVXI1Qd+CA7Uz1F1Cy4T9FfguqBYuQki8Od0KOkv87MixUuzJ6o9fGZ86/
tWvDqnyZYOcU1NiiJA2KYIav6Suv7QjQFab29k1RsI5Q9v5JGKJzjOPm6fTs9CxhHDWT2cUsOwsh
yu9/cOLll/fcMJU+JAoHaZDo83ijutnJbD5UuDLNTrN+6/8p9nw2HXo0P5n6Hr1RrNV9pb8PcXIx
9+0Nk9yUoAULe7FQ79RDqzYC2MCGjw3zvUSRUTvrVqIhUkD71ToKvM2jBGWUeKeiaAR3TBJ9HD0N
PZ8GKmlw3s/X7UX27FlFiZREKt8wr6ybVjw2ZOZe8RGbOWqlOrQKUJG5aBn1cdWENtohj8cZRaO4
9sZIt57wHzOkb2aIjIKvkygw1I6bh92VyrcBw3DQy6SQ4PoWVE4YJqsaGzOdZdkITGhx1q7bEI1c
d9Pke9+xJ1yJG1i+dRu3l4JmR2ZC5Wsw8ICnhQR/uAp1tLoJJEULzG1E2lmx0Q84055oMZT1kD6S
VA+iwFOHDgy/Yc326VYa1oInAf2oFpC6hLAbYgVTikg43r+opBwgJ+T6AvL+zv8DQjD2fqIoMMvB
M+s9ecimJyHWij2OVMQ6ByeK3KjRX+EdE9Psa0Vz/7XiEk6o9NXRHnR0Ffn74/D96hcAAAD//wMA
UEsDBBQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzs
WUtvGzcQvhfof1jsvbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqObkVy6qVAgbTooQF666EoGqAB
GvTSH2PAQZv+iA65L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWOMReExW2/eqviezgesTGJg7b/
aLD92W3fExLFY0RZjNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSLddT2QymT9ZUVMQIyErdYgmN4
NmE8QhJuebAy5ugEFojoymql0lyJEIn9DZAolaAehX+xFIoworyvxGAvRhGsfjCZkBHW2PFRVSHE
THQp944Rbfsgc8xOBviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3rf8yvoxhfLSq1+TBsFi0Xm/U
m5uFfA2gchHXa/WavWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZWrWrhDfm1BZ03G+pn4TUolV9f
wG9vd8GKFl6DUnxjAd/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0gK40mrVuvtsCMmF0xwlfa9S3
W6uZ8BIF0VBEl1piwmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJkBNvlwQhBF6CYiaAXFmtbFdq
8F/96vpKexStY2RwK71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785ff776YsXp89/zdbWoiy+HRQH
Jt/7n77559WX3t+//fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPvXr978/rs+6//+vmlQ/omR0MT
PiARFt4+PvEesgg26NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+GKHLgOti242MOqcYFvDd9ainc
D/lUEofEB2FkAfcYox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx5eXeNIEcS1wiuyG21DykKJYo
wDGWnnrGjjB27O4JIZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tgl5lLQfC3ZZu9x16HUdeut/Cx
jYR3A1GH8gNMLTPeQ1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT5vXGWAgXzwGH/RpOfwBpxu32
PTqLbCSX5MglcxcxZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY/Yaoe/ADipe6+zHBlrvPzwaP
IMOaKpUBop5MucOX9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYuxhSdoDHG3qPPHRp0WGLZvFT6
fghZZQe7Aus+smNV3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYojxJdJ3gevmzbvQamLXAFwQEdH
JnCfQL8H8eI0yoEAGUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5YaF3gvgQdfmgcSu8nzQdsMELUW
KANmgKDLcKVbYLHcX7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+jf+u94EO4+yHV46X7Xr6Hbdg
K1ldstNZlkx25vqbZbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa/3/f0yx7n286mWX9xk0n40OH
cdPJZMOV6+lkyuYF+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z8TYQFZ+ebuJiCpiEcKnKHCxg
4QKONI/HmfyCyLAfogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPjdNhZrarBZlpZBZIlvdIo6DCo
kim62SoHeIV4rW2gB625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEronV2LFmsOLW4r8bmrFrQA1Qqv
wAe3B5/pbb9RBxZggnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSUnl5Tui7dntpdGmoX8LSlhBFu
thLaMrrBEyF8BmfRqagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1NfDN5wYam5mCxt5J22/WGhAy
I5S0/QkMjeEySiB2hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNmg4hIzD1Koravtl+4gcY6h2jd
qquQED5a5dYgrXxsyoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86WHGyKbi7H45PvCGd8ocIQqzR
qioDjomAs4Nqas0xgcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnMU7hO5YU6+q6wgXGX7RkMapgk
K4TDQBVY06hWNS2qRqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNztrxakTe0yk0MOc2s8Gnqnk+5
a3mum+sTiioBBi/s56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNUu0iRMLJ+Mxc7Z7eiRjiXA+KV
Kj/wzUctkCZ5X6kt7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0qGlzBmTOUi/SguO1nFzkFnqeU
AlPLKbUcU88p9ZzSyCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBmvYV9+r/xLwAAAP//AwBQSwME
FAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2lu
ZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7Dez
TfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aS
GtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UX
FqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMA
AAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEA
AAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAPAkFuokC
AADfBgAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBL
AQItABQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAAAOYEAABjbGlwYm9hcmQvdGhl
bWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAADsM
AABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBn
AQAAPg0AAAAA
">
 <v:shape id="Shape_x0020_198705" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="4" height="18" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->وسیزویدك بھذا التأكید .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسیة لبومالیدوماید أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم 6). إذا كنت تعتقدین أنھ قد تكون لدیك حساسیة، فأطلبي المشورة من طبیبك.</p><p>&nbsp;</p><p dir="RTL">إذا كنت غیر متأكدة ما إذا كان أي من الشروط المذكورة أعلاه تنطبق علیك، فتحدثي مع طبیبك أو الصیدلي أو الممرضةقبل تناول إمنوفید.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>التحذیرات والاحتیاطات</strong>&nbsp;</p><p dir="RTL">تحدث إلى طبیبك أو الصیدلي أو الممرضة قبل تناول إمنوفید إذا:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدیك في أي وقت مضى جلطات دمویة. خلال العلاج بإمنوفید یكون لدیك زیادة في خطر الإصابة بجلطات دمویة في الأوردة والشرایین. قد یوصي طبیبك أن تتناول علاجات إضافیة (مثل الوارفارین) أو تخفیض جرعة إمنوفید لتقلیل فرصة حصول الجلطات الدمویة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لدیك في أي وقت مضى حساسیة مثل الطفح الجلدي، والحكة والتورم، والشعور بالدوار أو صعوبة في التنفس حین تتناول أدویة ذات صلة تسمى &#39;الثالیدوماید&#39; أو &#39;لینالیدوماید&#39;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لدیك نوبة قلبیة، قصور في القلب، صعوبة في التنفس، أو إذا كنت تدخن، أو إرتفاع في ضغط الدم أو إرتفاع في مستویات الكولسترول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك كمیة عالیة من الورم في جمیع أنحاء الجسم، بما في ذلك نخاع العظم. وھذا یمكن أن یؤدي إلى حالة حیث تتكسر الأورام مؤدیة إلى مستویات غیر عادیة من المواد الكیمیائیة في الدم التي یمكن أن تؤدي إلى الفشل الكلوي. قد تصاب أیضااً بضربات غیر متساویة للقلب. وتسمى ھذه الحالة متلازمة تحلل الورم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك أو كان لدیك في أي وقت مضى إعتلال عصبي ( تلف الأعصاب مما یسبب نخز أو ألم في الیدین أو القدمین.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لدیك أو كان لدیك في أي وقت مضى التھاب الكبد الفیروسي بي. العلاج باستخدام إمنوفید قد ینشط التھاب الكبد الفیروسي بي لدى المرضى الذین یحملون الفیروس، مما یؤدي إلى عودة الالتھاب. یجب أن یتأكد طبیبك ما إذا كان قدسبق إصابتك بالتھاب الكبد الفیروسي بي.</p><p dir="RTL">&bull; إذا كنت تختبر أو قد اختبرت في الماضي مزیج ًامن أي من الأعراض التالیة: طفح على الوجھ أو طفح جلدي&nbsp;&nbsp;&nbsp; ممتدّ، أوإحمرار الجلد، أو حمى مرتفعة، أو أعراض تشبھ أعراض الانفلونزا، أو&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخّم في العقد اللیمفاویة (علامات تدل على ردفعل جلدي حاد یسمى التفاعلات الدوائیة مع فرط الحمضات الأعراض الجھازیة أو متلازمة فرط الحساسیة للمخدرات أومتلازمة انحلال البشرة النخري السمي (TEN) أو متلازمة ستیفنز جونسون (SJS). أنظر&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أیضًاالجزء 4 &quot;التأثیرات الجانبیة المحتملة&quot;).</p><p dir="RTL">من المھم أن تلاحظ أن المرضى الذین یعانون من الورم النقوي المتعدد ویعالجون ببومالیدوماید قد تتطور لدیھم أنواع إضافیة من السرطان، ولذلك ینبغي على طبیبك أن&nbsp; یقّیم منافع ومخاطر العلاج بعنایة عندما یوصف لك ھذا الدواء.&nbsp;</p><p dir="RTL">أخبر طبیبك أو الممرضة على الفور إذا شعرت في أيِّ&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;وقتٍ أ ثناء العلاج أو عده أن ك: تعاني من عد م وضو ح الرؤة أ و من فقدان الرؤة أو ازدواج في الرؤة،&nbsp; أو صعو ة في &nbsp;&nbsp; ُّ&nbsp; التحدث أ و ضعف ف ي الذ ار ع أو الساق أو تغُّ&nbsp; یر في طرق ة المش ي أو مشاكل ف ي التواز ن أو تنمی ل مستمر أ و انخفا ض الإحسا س أو فقدا ن الإحساس أ و فقدان الذاكر ة أو الا ر باكت. قد تشی ر ل تلك الأع ار ض إلى إصابت ك&nbsp; حال ة دماغی ة خطیر ة&nbsp; ومُمیتة تعر ف اس م اعتلال بیضاء الدماغ متعدد البؤر المترقي&nbsp; (PML). إذا نت تعاني من أيٍّ من هذه الأع ارض قبل العلا ج إمنوفید ؛ أخبر طبیب ك عن أيِّ&nbsp; تغییر ف ي تل ك الأع ارض .</p><p>&nbsp;</p><p dir="RTL">في نھایة العلاج یجب أن تعید كل الكبسولات غیر المستعملة إلى الصیدلي.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>الحمل ومنع الحمل والرضاعة الطبیعیة - معلومات للنساء والرجال&nbsp; </strong></p><p dir="RTL">یجب أن یتبع ما یلي كما جاء في برنامج<em>i-SECURE </em>&nbsp;لبومالیدوماید الخاص بمنع الحمل.&nbsp;</p><p dir="RTL">عند تناول إمنوفید ، لا یجب أن تصبح النساء حوامل أو الرجال&nbsp; آباء. ذلك لأنھ من المتوقع لبومالیدوماید أن یؤذي الطفلالذي لم یولد بعد. ینبغي علیك وعلى شریكك إستخدام أسالیب فعالة لمنع الحمل أثناء تناول ھذا الدواء .&nbsp;</p><p dir="RTL"><strong>النساء&nbsp; </strong></p><p dir="RTL">لا تتناولي إمنوفید إذا كنت حاملاحاملاً، أو تعتقدي أنك قد تكوني حاملاحاملاً أو تخططي لتصبحي حامًلاً. ذلك لأنھ من المتوقع لھذا الدواء أن یؤذي الطفل الذي لم یولد بعد. قبل البدء في العلاج، یجب علیك إبلاغ الطبیب إذا كنت قادرة على أن تصبحي حاملاحاملاً، حتى لو كنت تعتقدین أن ھذا أمر غیر مرجح.&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قادرة على أن تصبحي &nbsp;حاملاً:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب إستخدام طرق فعالة لمنع الحمل لمدة 4 أسابیع على الأقل قبل بدء العلاج، طوال الفترة الذي تتناولین فیھ العلاج ، ولغایة 4 أسابیع على الأقل بعد وقف العلاج. تحدثي مع طبیبك حول أفضل طریقة لمنع الحمل بالنسبة لك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في كل مرة یكتب لك فیھا الطبیب وصفة طبیة، سوف یضمن لك فھم التدابیر اللازمة التي یجب إتخاذھا لمنع الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سیقوم الطبیب بترتیب إختبارات الحمل قبل العلاج، وكل 4 أسابیع على الأقل أثناء العلاج، و 4 أسابیع على الأقل بعد إنتھاء فترة العلاج.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحت &nbsp;حاملاًعلى الرغم من إتخاذ التدابیر الوقائیة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب إیقاف العلاج فوراَ والتحدث مع طبیبك على الفور</p><p dir="RTL">الرضاعة الطبیعیة:&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL">من غیر المعروف ما إذا كان إمنوفید یمر في حلیب ثدي الإنسان. أخبري طبیبك إذا كنت ترضعین طفلك &nbsp; &nbsp;طبیعیًاأو تنوین إرضاعھ &nbsp;&nbsp;&nbsp; &nbsp;طبیعیًا. سوف ینصحك طبیبك إذا كان یجب وقف أو مواصلة الرضاعة الطبیعیة.&nbsp;</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>الرجال</strong>&nbsp;</p><p dir="RTL">یمر إمنوفید في السائل المنوي البشري.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت شریكة حیاتك حاملاًأو قادرة على أن تصبح حامًلاً، فیجب إستخدام الواقي الذكري طوال الوقت الذي تتناول فیھ العلاج ولمدة 7 أیام بعد إنتھاء العلاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبحت شریكة حیاتك حامًلاً أثناء تناولك إمنوفید، فأخبر طبیبك &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فورًا. یجب على شریكة حیاتك أن تخبرطبیبھا على الفور.</p><p dir="RTL">یجب أن لا تتبرع بسائل منوي أو حیوانات منویة أثناء العلاج ولمدة 7 أیام بعد إنتھاء العلاج.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>التبرع بالدم وإختبارات الدم</strong>&nbsp;</p><p dir="RTL">یجب أن لا تتبرع بالدم خلال فترة العلاج ولمدة 7 أیام بعد إنتھاء العلاج.&nbsp;</p><p dir="RTL">ستجرى لك إختبارات دم عادیة قبل وأثناء العلاج بإمنوفید. ذلك لأن الدواء قد یسبب إ&nbsp;&nbsp; نخفاضًافي عدد خلایا الدم التي تساعد على مكافحة العدوى (الخلایا البیضاء) وفي عدد الخلایا التي تساعد على وقف النزیف (الصفائح الدمویة) .&nbsp;</p><p>&nbsp;</p><p dir="RTL">سیطلب منك طبیبك أن یجرى لك فحص دم:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل أسبوع لأول 8 أسابیع من العلاج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; على الأقل كل شھر بعد ذلك طالما كنت تتناول إمنوفید.</p><p dir="RTL">ونتیجة لھذه الاختبارات، قد یغیر طبیبك جرعة إمنوفید أو وقف العلاج. یمكن للطبیب أیضااً تغییر الجرعة أو إیقاف الدواءبسبب صحتك العامة.&nbsp;&nbsp;</p><p dir="RTL"><strong>الأطفال والمراھقین</strong>&nbsp;</p><p dir="RTL">لا ینصح بتناول إمنوفید من قبل الأطفال والشباب الذین ھم دون سن 18 عاماً.</p><p dir="RTL"><strong>الأدویة الأخرى و إمنوفید</strong>&nbsp;</p><p dir="RTL">أخبر طبیبك أو الصیدلي أو الممرضة إذا كنت تتناول، أو تناولت &nbsp;&nbsp; &nbsp;مؤخرًاأو قد تتناول أي أدویة أخرى. ذلك لأن إمنوفیدیمكن أن یؤثر على الطریقة التي تعمل بھا بعض الأدویة الأخرى. یمكن أن تؤثر أیضااً بعض الأدویة الأخرى على الطریقة التي یعمل بھا إمنوفید.&nbsp;</p><p>&nbsp;</p><p dir="RTL">على وجھ الخصوص، أخبر طبیبك أو الصیدلي أو الممرضة قبل تناول إمنوفید إذا كنت تتناول أي من الأدویة التالیة:&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الفطریات مثل كیتاكونازول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض المضادات الحیویة (على سبیل المثال سیبروفلوكساسین، إینوكساسین)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الإكتئاب مثل فلوفوكسامین.</p><p dir="RTL"><strong>القیادة وإستخدام المكائن</strong>&nbsp;</p><p dir="RTL">بعض الناس یشعرون بالتعب والدوار والإغماء، والإرتباك أو أقل إنتباھااً عند تناول إمنوفید. إذا حدث ھذا لك، لا تقود أو تشغل آلات أو مكائن.</p><p dir="RTL">یحتوي إیمنوفید على الصودیوم&nbsp;</p><p dir="RTL">یحتوي ھذا الدواء على أقل من 1 ملیمول من الصودیوم( 23 ملغ) لكل كبسولة ، لذلك فھو یعتبر أس اسًا خالًیًاً من الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">یجب أن یعطى إمنوفید لك من قبل طبیب من ذوي الخبرة في علاج الورم النقوي المتعدد.&nbsp;</p><p dir="RTL">دائمااً خذ أدویتك تمامااً كما أخبرك طبیبك بذلك. تحقق من طبیبك أو الصیدلي أو الممرضة إذا لم تكن متأكداً.</p><p dir="RTL">متى تأخذ إمنوفید مع الأدویة الأخرى&nbsp;</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع بورتیزومیب ودیكسامیثازون&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر المنشورات التي تأتي مع بورتیزومیب ودیكسامیثازون لمزید من المعلومات حول استخدامھا وآثارھا.&nbsp;</p><p dir="RTL">&bull;&nbsp; یؤخذ إمنوفید، بورتیزومیب و دیكسامیثازون في &quot;دورات العلاج&quot;. تستمر كل دورة 21 یوًمًا( 3 أسابیع.)&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر إلى الرسم البیاني أدناه لترى ما یجب القیام بھ في كل یوم من أیام دورة الثلاثة أسابیع:&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل یوم ، انظر إلى الرسم البیاني أدناه وابحث عن الیوم الصحیح لمعرفة الأدویة التي یجب تناولھا.&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأیام ، تتناول جمیع الأدویة الثلاثة ، في بعض الأیام<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_94614" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAU9fT64sCAADfBgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzMVdtu2zAMfR+wfxD83tpJc2mDpgXa
rnkZtqLpPoCV5diYLAuS4jl/P4qW7Kxbi2J7WQJYskge8lBH8uV1V0vWCmOrRq2TyWmWMKF4k1dq
t06+Pd2fnCfMOlA5yEaJdXIQNrm++vjhElY7A7qsOEMEZVewTkrn9CpNLS9FDfa00UKhrWhMDQ5f
zS7NDfxA5Fqm0yxbpDVUKrkaoe7AAdub6i+gZMO/i/wWVAsWISVfHa+EGiX/d2RYqXZj9FY/GF85
/9I+GFbl6wQ7p6DGFiVpMAQ3fE1fRO1GgK4wtfdvioJ1hHLwT8IQnWMcF2fT+WyeMI6WyfJimc1D
ivLrH4J4+emtMCylT4mTozJo6ut4hd3FbDGZRYYb0+w165f+H7KL5XTo0fnZ1PfoFbJW90x/38Rp
draYTyLPbQlasLAWifqgHlq1EcAGNbxvM98qFBW1t24jGhIFtJ+to8S7PM6gjDPeqTg1gjsmST6O
noaez4OUNDgf53n7KfvhVUWFlCQq3zBvrJtWPDXk5l7oEZs5WqU69gpQUbnoGe1x1IQ2+qGOxz2K
TnHsnfFA9YJ/nyOdmSEzTjxPksDAHRePuyuVbwOm4aDXSSHB9S2onDBMVjU2ZrrMshGY0OJeu25L
MnLdTZMffMeecSRtIH3rtu4gBe0duQmVP4CBR7wtJPjLVaiTzU0QKXpgbSPS3oqtfsQ97YUWU1kP
6TNJ9SgKvHXowvAL1uyeb6VhLXgR0I+4gNQlhNWQK7hSRsLx8UUl5QA5odBfIO/v/D8gBGcfJ4oC
qxwisz6Sh2p6ESJX7HGUIvIcgihzo8Z4hd+YWGbPFd39acUh3FDpi6s92OhT5L8fx+9XPwEAAP//
AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnht
bOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrroSga
oAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6xMYmD
tv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjISt1iC
Y3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY8VFV
IcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGwWLRe
b9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfhNSiV
X1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTHCV9r
1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBcWa1s
V2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1taiLL4d
FAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD+iZH
QxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8N31q
KdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbUPKQo
lijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR1663
8LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/AGnG
7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGWu8/P
Bo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRYYtm8
VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtcAXBA
R0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB2wwQ
tRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpftevod
t2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3GTSfj
Q4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRwqcoc
LGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW90ijo
MKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasWtADV
Cq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfwtKWE
EW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knbb9Ya
EDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iBxjqH
aN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3yhwhC
rNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZftGQxq
mCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazwaeqe
T7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JGOJcD
4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcXOQWe
p5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8DAFBL
AwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3
aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPs
N7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4n
xpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTL
pRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAA
EwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/x
wQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBT19Pr
iwIAAN8GAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1s
UEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAAAAAA6AQAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAA
PQwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAF
AGcBAABADQAAAAA=
">
 <v:shape id="Shape_x0020_203651" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCg/a93xgAAAN8AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvhb5DOAXvNKtSka1RpCAoSEFX8PZ0c/YHk5PtJurq05tCwcthZr5h5svOGnGl1teOFYyGCQji
3OmaSwXHbD2YgfABWaNxTAru5GG5eOvNMdXuxnu6HkIpIoR9igqqEJpUSp9XZNEPXUMcvcK1FkOU
bSl1i7cIt0aOk2QqLdYcFyps6Kui/Hy4WAXl6Wf72NG3mUjHu2xtimP2WyjVf+9WnyACdeEV/m9v
tIJxMpl+jODvT/wCcvEEAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAoP2vd8YAAADfAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="4" height="18" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1027" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->دواءین أو واحد فقط، وفي بعض الأیام لا شيء على الإطلاق</p><p dir="RTL"><strong>إمن</strong>: إمنوفید;<strong> بور</strong>: بورتیزومیب;<strong> دیكس</strong>: دیكسامیثازون</p><p dir="RTL">دورة 1 إلى 8</p><table border="0" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">إسم الدواء&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>بور</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">یوم&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٣</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٤</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٥</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٦</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٧</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٨</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٩</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٠</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١١</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٢</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٣</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٤</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٥</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٦</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٧</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٨</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٩</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢٠</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢١</p></td></tr></tbody></table><p dir="RTL">دورة 9 وما بعد</p><table border="0" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">إسم الدواء&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>بور</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">یوم&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٣</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٤</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٥</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٦</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٧</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٨</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٩</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٠</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١١</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٢</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٣</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٤</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٥</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٦</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٧</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٨</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١٩</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢٠</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢١</p></td></tr></tbody></table><p dir="RTL">&bull;&nbsp; بعد الانتھاء من كل دورة 3 أسابیع، ابدأ دورة جدیدة.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع دیكسامیثازون فقط&nbsp;</p><p dir="RTL">&bull;&nbsp; انظر المنشور الذي یأتي مع دیكسامیثازون لمزید من المعلومات حول استخدامھ وآثاره.</p><p dir="RTL">یؤخذ إمنوفید و دیكسامیثازون في دورات علاجیة.&nbsp;</p><p dir="RTL">&nbsp;&nbsp; كل دورة تستمر 28&nbsp;&nbsp; یومًا( 4 أسابیع.)</p><p dir="RTL">&bull;&nbsp; انظر إلى الرسم البیاني أدناه لترى ما یجب أن تأخذ في كل یوم من أیام دورة الأربعة أسابیع:&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل یوم ، انظر إلى الرسم البیاني أدناه وابحث عن الیوم الصحیح لمعرفة الأدویة التي یجب تناولھا.&nbsp;</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في بعض الأیام، تأخذ الدواءین ، في بعض الأیام دواء واحد ، وفي بعض الأیام لا شيء على الإطلاق.</p><p dir="RTL"><strong>إمن</strong>: إمنوفید;<strong> دیكس</strong>: دیكسامیثازون</p><table border="0" cellspacing="0" cellpadding="0" style="width:465px"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">إسم الدواء&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p dir="RTL"><strong>دیكس</strong>&nbsp;</p></td><td style="vertical-align:top; width:1px"><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL"><strong>إمن</strong>&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">یوم&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &radic;</p></td><td style="vertical-align:top; width:1px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ١</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td style="vertical-align:top; width:1px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٢</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td style="vertical-align:top; width:1px"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; &radic;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp; ٣</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٤&nbsp; &nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٥</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٦</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" rowspan="15" style="vertical-align:top; width:136.4px"><p>&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٧</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &radic;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٨</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;&nbsp;&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٩</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٠</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١١</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٢</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٣</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٤</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &radic;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٥</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٦</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٧</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٨</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ١٩</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٠</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&radic;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢١</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp; &radic;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٢</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٣</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٤</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٥</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٦</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٧</p></td></tr><tr><td style="vertical-align:top; width:185.6px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top; width:136.4px"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp; ٢٨</p></td></tr></tbody></table><p dir="RTL">&bull;&nbsp; بعد الانتھاء من كل دورة 4 أسابیع ، ابدأ دورة جدیدة.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL"><strong>الكمیة الممكن تناولھا من إمنوفید مع الأدویة الأخرى</strong>&nbsp; <strong>إمنوفید مع بورتیزومیب ودیكسامیثازون</strong>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من إمنوفید ھي 4 ملغم یومیاً .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من بورتیزومیب سیعمل بھا طبیبك واستنادا إلى طولك ووزنك (مساحة سطح الجسم 1.3ملغم /متر مربع).&nbsp;</p><p></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة البدایة الموصى بھا من الدیكسامیثازون ھي 20 ملغم في الیوم. ومع ذلك ، إذا كان عمرك أكثر من 75، فإن جرعة البدایة الموصى بھا ھي 10 ملغم یومًیًاً.</p><p>&nbsp;</p><p dir="RTL">إمنوفید مع دیكسامیثازون فقط&nbsp;</p><p>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بھا من إمنوفید ھي 4 ملغم یومیا.</p><p>&nbsp;</p><p dir="RTL">جرعة البدایة الموصى بھا من دیكسامیثازون ھي 40 ملغم یومیااً.&nbsp; ومع ذلك ، إذا كان عمرك أكثر من 75، فإن جرعة البدایة الموصى بھا ھي 20 ملغ یومًیًاً.&nbsp;</p><p dir="RTL">قد یحتاج طبیبك إلى تقلیل جرعة إمنوفید، بورتیزومیب أو دیكسامیثازون أو وقف واحد أو أكثر من ھذه الأدویة بناء على نتائج إختبارات الدم الخاصة بك، وحالتك العامة، إن الأدویة الأخرى التي تتناولھا (مثل سیبروفلوكساسین، إینوكساسینوفلوفوكسامین) وإذا ما كنت تواجھ تأثیرات جانبیة (وخاصة الطفح الجلدي أو الانتفاخ) من العلاج. إذا كنت تعاني من مشاكل في الكلى أو الكبد فسوف یتحقق طبیبك من حالتك بعنایة فائقة أثناء تناولك ھذا الدواء.&nbsp;</p><p dir="RTL"><strong>كیف تتناول إمنوفید&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكسر أو تفتح أو تمضغ الكبسولات. إذا ما لامس جلدك مسحوق إمنوفید من كبسولة مكسورة، إغسل الجلد فوراً وجیداً بالصابون والماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبلع الكبسولات بأكملھا، ویفضل مع الماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یمكنك أن تتناول الكبسولات إما مع أو بدون الطعام.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول إمنوفید في نفس الوقت تقریبااً كل یوم.</p><p>&nbsp;</p><p dir="RTL">لإخراج الكبسولة من التغلیف اضغط على أحد جوانب الكبسولة فقط لإخراجھا من الرقاقة المعدنیة .&nbsp;</p><p dir="RTL">لا تضعط بقوة على الكبسولة من الوسط فقد تنكسر.&nbsp;</p><p>&nbsp;</p><p><img alt="" width="609" height="802" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p dir="RTL">سیحدد لك الطبیب كیفیة ومواعید تناول إمنوفید وإذا كانت لدیك مشاكل في الكلى تقوم بعملیة الغسیل الكلوي.&nbsp;</p><p dir="RTL"><strong>مدة العلاج بإمنوفید</strong>&nbsp;</p><p dir="RTL">یجب أن تستمر دورات العلاج حتى یخبرك طبیبك بالتوقف.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت إمنوفید أكثر مما یجب</strong>&nbsp;</p><p dir="RTL">إذا تناولت إمنوفید أكثر مما یجب فتحدث إلى الطبیب أو إذھب إلى المستشفى على الفور. خذ علبة الدواء معك.&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسیت أن تتناول إمنوفید </strong>&nbsp;&nbsp;</p><p dir="RTL">إذا نسیت أن تتناول إمنوفید في یوم ما عندما یجب أن تتناولھ، فتناول الكبسولة القادمة كالمعتاد في الیوم التالي. لا تزید عدد الكبسولات التي تتناولھا للتعویض عن عدم تناولك إمنوفید في الیوم السابق.&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا كان لدیك أي أسئلة أخرى عن إستعمال ھذا الدواء، فإسأل طبیبك أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة، یمكن لھذا الدواء أن یسبب تأثیرات جانبیة، وإن لم تحصل للجمیع.&nbsp;</p><p dir="RTL">التأثیرات الجانبیة الخطیرة&nbsp;&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول إمنوفید ومراجعة الطبیب على الفور، إذا لاحظت أي من التأثیرات الجانبیة الخطیرة التالیة: - قد تحتاج إلى علاج طبي عاجل:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، قشعریرة، إلتھاب الحلق، السعال، قرحة الفم أو أي علامات أخرى للعدوى (نتیجة لعدد أقل من خلایا الدم البیضاء، التي تكافح العدوى.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف أو كدمات من دون سبب،&nbsp; بما في ذلك نزیف الأنف ونزیف الأمعاء أو المعدة (نتیجة للتأثیرات على خلایا دمویة تسمى &#39;الصفائح الدمویة.)&#39;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنفس سریع ،نبض سریع ،حمى وقشعریرة ، تبول القلیل من البول إلى عدم التبول ، الغثیان والقيء ،الارتباك ،فقدان الوعي (بسبب إلتھاب في الدم یسمى الإنتان أو الصدمة الإنتانیة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسھال شدید ومستمر أو دموي (ربما مع ألم في المعدة أو حمى) تسببھ بكتیریا تسمى المطثیات العسیرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، أو ألم في الساق وتورم، وخاصة في أسفل الساق أو الشظیة (التي تسببھا الجلطات الدمویة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق في التنفس (من عدوى خطیرة في الصدر، التھاب الرئة، قصور القلب أو تجلط الدم.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجھ والشفتین واللسان والحلق، والتي قد تسبب صعوبة في التنفس (نظرا لنوع خطیر من الحساسیة یسمى الوذمة الوعائیة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع سرطان الجلد (سرطان الخلایا الحرشفیة وسرطان الخلایا القاعدیة)، التي قد تسبب تغیرات في مظھر بشرتك أو أورام بالجلد. إذا لاحظت أي تغییرات على بشرتك عند تناول إمنوفید، أخبر طبیبك في أسرع وقت ممكن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكرار الإصابة بالتھاب الكبد الفیروسي بي، الذي یمكن أن&nbsp; یسبب إصفراًرًا بالجلد والعینین، لون البول البني الداكن ،آلام بالجانب الأیمن من البطن ،الحمى والغثیان أوالشعور بالمرض. أخبر طبیبك فوًرًا إذا لاحظت أي من ھذه الأعراض.</p><p dir="RTL"><strong>توقف عن تناول إمنوفید واستشر الطبیب على الفور </strong>إذا لاحظت أي من الآثار الجانبیة الخطیرة المذكورة أعلاه - قد تحتاج إلى علاج طبي عاجل.</p><p dir="RTL"><strong>التأثیرات الجانبیة الأخرى</strong>&nbsp;</p><p dir="RTL"><strong>شائعة&nbsp; جدًا</strong>: قد تؤثر على أكثر من 1 على 10 أشخاص&nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضیق في التنفس (الزلة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات الرئتین (الالتھاب الرئوي والتھاب الشعب الھوائیة.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات الأنف ،الجیوب الأنفیة والحنجرة التي تسببھا البكتیریا أو الفیروسات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلایا الدم الحمراء ، والتي قد تسبب فقر الدم مما یؤدي إلى التعب والضعف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات الدم من البوتاسیوم (نقص بوتاسیوم الدم) ، والذي قد یسبب الضعف ، تشنجات العضلات ، آلام العضلات ، الخفقان ، وخز أو تنمیل ، ضیق التنفس ، وتغیرات المزاج.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستویات السكر في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشھیة.إمساك، إسھال أو الغثیان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن تكون مریًضًا (القيء.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في الطاقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم أو البقاء نائما.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة ، الرعشھ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات و. ضعف العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العظام وآلام الظھر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنمیل ،وخز أو حرقان في الجلد ، آلام في الیدین أو القدمین (إعتلال عصبي حسي حركي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجسم، بما في ذلك تورم في الذراعین أو الساقین.</p><p>&nbsp;</p><p dir="RTL"><strong>الشائعة</strong>: قد تؤثر على ما یصل إلى 1 على 10 أشخاص&nbsp; &nbsp;&nbsp; السقوط&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزیف داخل الجمجمة&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القدرة على الحركة أو الشعور (الإحساس) في یدیك ،ذراعیك ،قدمیك وساقیك بسبب تلف الأعصاب( إعتلال عصبي حسي حركي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنمیل ، حكة ، وشعور دبابیس وإبر على جلدك( مََذَلَ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار في رأسك ، مما یجعل من الصعب الوقوف والتحرك بشكل طبیعي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم ناتج عن السوائل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الطفح الجلدي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ِھِْرْبِ ٌسٌِ نُطُا ِقِيِّ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب وعدم انتظامھا (الرجفان الأذیني).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات القلبیة (ألم في الصدر یمتد إلى الذراعین والرقبة والفك، والشعور بالتعرق وصعوبة التنفس، والشعور بالغثیانأو التقیؤ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر ، التھاب في الصدر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زیادة ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم الحمراء والبیضاء والصفائح الدمویة في نفس الوقت (قلة الكریات الشاملة والتي سوف تجعلكأكثر عرضة للنزیف والكدمات. قد تشعر بالتعب والضعف، وضیق التنفس وقد تكون أكثر عرضة للإصابة بالالتھاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلایا الدم البیضاء (نوع واحد من خلایا الدم البیضاء) غالبًا ما یكون ناتًجًا عن إلتھاب (اللمفاویات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستویات المغنیسیوم في الدم (نقص مغنیسیوم الدم) ، والذي قد یسبب التعب ، الضعف العام ، تشنجات العضلات ، إنزعاج ، وقد یؤدي إلى انخفاض مستویات الكالسیوم في الدم (نقص كلس الدم) ، مما قد یؤدي إلى تنمیل أو وخز في الیدین أو القدمین أو الشفاه ، تشنجات العضلات ، ضعف العضلات ،الدوار والارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الدم من الفوسفات (نقص فوسفات الدم) ، والذي قد یسبب ضعف العضلات و<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span> SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_92821" o:spid="_x0000_s1026"
 style='width:3.35pt;height:14.15pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA0iOVFIsCAADfBgAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzMVdtu2zAMfR+wfxD83trxmuaCJgXa
rnkZtqLpPoCV5diYLBuS4jp/P4qW7Cxbi2J7WQJYskge8lBH8tV1V0nWCm3KWq2iyXkSMaF4nZVq
t4q+P92fzSNmLKgMZK3EKjoIE12vP364guVOQ1OUnCGCMktYRYW1zTKODS9EBea8boRCW17rCiy+
6l2caXhB5ErGaZJcxhWUKlqPUHdgge11+RdQsuY/RHYLqgWDkJIvj1d8jZL/OzIsVbvRzbZ50K5y
/rV90KzMVhF2TkGFLYpib/Bu+BqfRO1GgC7XlfOv85x1hHJwT8IQnWUcFy/S6cU0Yhwtk9lilkx9
iuLbH4J48fmtMCylT4mTozJo6up4hd0inaeTwHCj633D+qX/h+zlLB16NP+Uuh69QtY0PdPfNzFN
5tPFIvDcFtAI5tcCURfUQ6s2ABivhvdt5luFoqL2xm5ETaKA9ouxlHiXhRkUYcY7FaZacMskycfS
U9PzeZBSA9bFOd5uyl6cqqiQgkTlGuaMVd2Kp5rc7IkesZmjVapjLw8VlIuewR7GhtBGP9TxuEfB
KYy9Mx6oXvDvc6QzM2TGieNJEhi44+Jxd6VybcA0HJpVlEuwfQtKKzSTZYWNSWdJMgITWthr221J
Rra7qbOD69gzjqQNpG/s1h6koL0jN6GyB9DwiLeFBHe5CnW2ufEiRQ+sbUTaG7FtHnFPe6GFVMZB
ukxSPYocbx26MNyC0bvnW6lZC04E9CMuIJsC/KrP5V0pI+G4+LyUcoCcUOgvkPd37u8RvLOLE3mO
VQ6RSR/JfTW9CJEr9jhIEXkOQZS5VmO8wm9MKLPniu7utOLgb6j45Gr3NvoUue/H8fv6JwAAAP//
AwBQSwMEFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnht
bOxZS28bNxC+F+h/WOy9sWS9YiNyYMly3MQvREqKHCmJ2mXMXS5Iyo5uRXLqpUCBtOihAXrroSga
oAEa9NIfY8BBm/6IDrkvUqLiB1wgKGwBxu7sN8PhzOzM7PDO3WcR9Y4xF4TFbb96q+J7OB6xMYmD
tv9osP3Zbd8TEsVjRFmM2/4MC//uxqef3EHrI0qSIUN8PAhxhD0QFIt11PZDKZP1lRUxAjISt1iC
Y3g2YTxCEm55sDLm6AQWiOjKaqXSXIkQif0NkCiVoB6Ff7EUijCivK/EYC9GEax+MJmQEdbY8VFV
IcRMdCn3jhFt+yBzzE4G+Jn0PYqEhAdtv6L//JWNOytoPWOicgmvwbet/zK+jGF8tKrX5MGwWLRe
b9Sbm4V8DaByEddr9Zq9ZiFPA9BoBDtNdbFltla79QxrgNJLh+yt1latauEN+bUFnTcb6mfhNSiV
X1/Ab293wYoWXoNSfGMB3+isdbZs+RqU4psL+FZlc6vesuRrUEhJfLSArjSatW6+2wIyYXTHCV9r
1Ldbq5nwEgXRUESXWmLCYrks1iL0lPFtACggRZLEnpwleIJGEJNdRMmQE2+XBCEEXoJiJoBcWa1s
V2rwX/3q+kp7FK1jZHArvUATsUBS+nhixEki2/59kOobkLO3b0+fvzl9/vvpixenz3/N1taiLL4d
FAcm3/ufvvnn1Zfe37/9+P7lt+nS83hh4t/98tW7P/78kHjYcWmKs+9ev3vz+uz7r//6+aVD+iZH
QxM+IBEW3j4+8R6yCDbo0B8P+eU4BiEiJsdmHAgUI7WKQ35PhhZ6f4YocuA62LbjYw6pxgW8N31q
KdwP+VQSh8QHYWQB9xijHcadVnig1jLMPJjGgXtxPjVxDxE6dq3dRbHl5d40gRxLXCK7IbbUPKQo
lijAMZaeesaOMHbs7gkhll33yIgzwSbSe0K8DiJOkwzI0IqmkmmHROCXmUtB8Ldlm73HXodR1663
8LGNhHcDUYfyA0wtM95DU4kil8gBiqhp8F0kQ5eS/RkfmbiekODpAFPm9cZYCBfPAYf9Gk5/AGnG
7fY9OotsJJfkyCVzFzFmIrfYUTdEUeLC9kkcmtjPxRGEKPIOmXTB95j9hqh78AOKl7r7McGWu8/P
Bo8gw5oqlQGinky5w5f3MLPitz+jE4RdqWaTR1aK3eTEGR2daWCF9i7GFJ2gMcbeo88dGnRYYtm8
VPp+CFllB7sC6z6yY1Xdx1hgTzc3i3lylwgrZPs4YEv02ZvNJZ4ZiiPEl0neB6+bNu9BqYtcAXBA
R0cmcJ9Avwfx4jTKgQAZRnAvlXoYIquAqXvhjtcZt/x3kXcM3sunlhoXeC+BB1+aBxK7yfNB2wwQ
tRYoA2aAoMtwpVtgsdxfsqjiqtmmTr6J/dKWboDuyGp6IhKf2wHN9T6N/673gQ7j7IdXjpftevod
t2ArWV2y01mWTHbm+ptluPmupsv4mHz8Tc0WmsaHGOrIYsa66Wluehr/f9/TLHufbzqZZf3GTSfj
Q4dx08lkw5Xr6WTK5gX6GjXwSAc9euwTLZ36TAilfTmjeFfowY+A75nxNhAVn55u4mIKmIRwqcoc
LGDhAo40j8eZ/ILIsB+iBKZDVV8JCUQmOhBewgQMjTTZKVvh6TTaY+N02FmtqsFmWlkFkiW90ijo
MKiSKbrZKgd4hXitbaAHrbkCivcyShiL2UrUHEq0cqIykh7rgtEcSuidXYsWaw4tbivxuasWtADV
Cq/AB7cHn+ltv1EHFmCCeRw052Plp9TVuXe1M6/T08uMaUUANNh5BJSeXlO6Lt2e2l0aahfwtKWE
EW62EtoyusETIXwGZ9GpqBdR47K+XitdaqmnTKHXg9Aq1Wjd/pAWV/U18M3nBhqbmYLG3knbb9Ya
EDIjlLT9CQyN4TJKIHaE+uZCNIDjlpHk6Qt/lcyScCG3kAhTg+ukk2aDiEjMPUqitq+2X7iBxjqH
aN2qq5AQPlrl1iCtfGzKgdNtJ+PJBI+k6XaDoiyd3kKGT3OF86lmvzpYcbIpuLsfjk+8IZ3yhwhC
rNGqKgOOiYCzg2pqzTGBw7AikZXxN1eYsrRrnkbpGErpiCYhyiqKmcxTuE7lhTr6rrCBcZftGQxq
mCQrhMNAFVjTqFY1LapGqsPSqns+k7KckTTLmmllFVU13VnMWiEvA3O2vFqRN7TKTQw5zazwaeqe
T7lrea6b6xOKKgEGL+znqLoXKAiGauVilmpK48U0rHJ2RrVrR77Bc1S7SJEwsn4zFztnt6JGOJcD
4pUqP/DNRy2QJnlfqS3tOtjeQ4k3DKptHw6XYTj4DK7geNoH2qqirSoaXMGZM5SL9KC47WcXOQWe
p5QCU8sptRxTzyn1nNLIKY2c0swpTd/TJ6pwiq8OU30vPzCFGpYdsGa9hX36v/EvAAAA//8DAFBL
AwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3
aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPs
N7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4n
xpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTL
pRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAA
EwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/x
wQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDSI5UU
iwIAAN8GAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1s
UEsBAi0AFAAGAAgAAAAhAJJ9h+AdBwAASSAAABoAAAAAAAAAAAAAAAAA6AQAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAA
PQwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAF
AGcBAABADQAAAAA=
">
 <v:shape id="Shape_x0020_208599" o:spid="_x0000_s1027" style='position:absolute;
  width:42672;height:179832;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="42672,179832" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l42672,r,179832l,179832,,e" fillcolor="#fdfdfd" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,42672,179832"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="5" height="19" src="file:///C:/Users/ph-a-/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:3.35pt;
 height:14.15pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]-->الإنزعاج أو الارتباك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى الكالسیوم في الدم (فرط كالسیوم الدم) ، مما قد یؤدي إلى تباطؤ ردود الفعل وضعف العضلات الھیكلیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستویات عالیة من البوتاسیوم في الدم، الذي قد یسبب ضربات قلب غیر طبیعیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستویات منخفضة من الصودیوم في الدم، الذي قد یسبب التعب والإرتباك، وإرتعاش العضلات، ونوبات (نوبات صرع) أو غیبوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستویات حمض الیوریك في الدم، ما قد یسبب نوع من التھاب المفاصل یسمى النقرس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم ، والذي قد یسبب الدوخة أو الإغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبھ الانفلونزا (الانفلونزا.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة أو جفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغییرات في طریقة تذوق الأشیاء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن ، تورم في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرتباك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإحباط (المزاج المكتئب.)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي، الاغماء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تَ َغَیُّ َمُّ&nbsp; في عینك (كاتاراكت).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج إختبار غیر طبیعیة للكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتھاب المسالك البولیة ، والتي قد تسبب إحساًسًاً حارًقًاً عند مرور البول ، أو الحاجة إلى التبول كثیًرًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الحوض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن.</p><p><strong>&nbsp; </strong></p><p dir="RTL"><strong>غیر شائعة</strong>: قد تؤثر على ما یصل إلى 1 على 100 شخص&nbsp; &nbsp;&nbsp; السكتة الدماغیة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھاب الكبد (الفیروسي) والذي یمكن أن یسبب حكة بالجلد، إصفرار الجلد وبیاض العینین (الیرقان)،&nbsp; لون البرازالشاحب، ولون البول الداكن وآلام في البطن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انھیار الخلایا السرطانیة مما یؤدي إلى سریان المركبات السامة في مجرى الدم (متلازمة انحلال الورم). ما قد یؤديإلى مشاكل في الكلى.</p><p dir="RTL">غیر معروفة (لا یمكن تقدیر التر دّ من البیانات المتاحة:)&nbsp;</p><p dir="RTL">&bull; الطفح الجلدي المنتشر، وارتفاع درجة حرارة الجسم، &nbsp;&nbsp; &nbsp;وتضخّم الغدد اللیمفاویة وغیرھا من أعضاء الجسم (التفاعلات الدوائیة مع فرط الحمضات والأعراض الجھازیة التي تعرف أیض ًاباسم متلازمة فروسیة أو مخاض فرط الحساسیة للمخدرات، أو انحلال البشرة النخري السمي أو متلازمة ستیفنز جونسون). إذا قمت بتطویر ھذه الأعراض ،علیك التوقف عن استخدام pomalidomide والاتصال بطبیبك أو الحصول على الرعایة الطبیة على الفور .أنظر&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أیضًاالجزء 2.<strong>الإبلاغ عن التأثیرات الجانبیة</strong>&nbsp;</p><p>اذا حصلت لك أي تأثیرات جانبیة، فتحدث مع طبیبك أو الصیدلي أو الممرضة. وھذا یشمل أي تأثیرات جانبیة محتملة من غیر المدرجة في ھذه النشرة. بإبلاغك عن التأثیرات الجانبیة یمكنك أن تساعد على توفیر مزید من المعلومات حول سلامةھذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إحفظ ھذا الدواء بعیداً عن نظر ومتناول الأطفال.&nbsp;</p><p dir="RTL">یخزن تحت أقل من 30 درجة مئویة.&nbsp;</p><p dir="RTL">لا تستعمل ھذا الدواء بعد إنتھاء تاریخ الصلاحیة المبین على الاصق والكارتون بعدEXP . تاریخ إنتھاء الصلاحیة یشیر إلى الیوم الأخیر من ذلك الشھر.&nbsp;</p><p dir="RTL">لا تستعمل إمنوفید إذا لاحظت أي ضرر أو علامات عبث في علبة الدواء .&nbsp;</p><p dir="RTL">لا تتخلص من أي أدویة عن طریق میاه الصرف الصحي أو النفایات المنزلیة. یجب أن یعاد أي دواء غیر مستعمل إلىالصیدلي في نھایة العلاج. وسوف تساعد ھذه التدابیر على حمایة البیئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن المادة الفعالة ھي بومالیدوماید</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى ھي مانیتول(E421)، ونشاء،&nbsp; بریجیلاتینایزد وفومارات ستیاریل الصودیوم.</p><p dir="RTL">إمنوفید 1 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 1 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم(E171) ، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172) والحبر الأبیض والأسود.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، جلایكول البروبیلین( E1520)، ھیدروكسید الأمونیوم( E527) (حبر أبیض) صمغ اللك ، أوكسید الحدید الأسود( E172)، غلیكول البروبیلین (E1520) وھیدروكسید الأمونیوم( E527) (حبر أسود.)</p><p dir="RTL">إمنوفید 2 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 2 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم(E171) ، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172)، إریثروسین( E127) والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض ،صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، غلیكول البروبیلین( E1520) وھیدروكسید الأمونیوم( E527).</p><p>&nbsp;</p><p dir="RTL">إمنوفید 3 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 3 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أوكسید التیتانیوم (E171)، إندیجوتین (E132)، أوكسید الحدید الأصفر</p><p dir="RTL">(E172) والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض ،صمغ اللك، ثاني أوكسید التیتانیوم( E171)، سیمیثیكون، غلیكول البروبیلین( E1520) وھیدروكسید الأمونیوم( E527).</p><p>&nbsp;</p><p dir="RTL">إمنوفید 4 ملغم كبسولة صلبة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كل كبسولة تحتوي على 4 ملغم من بومالیدوماید.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي غلاف الكبسولة على: الجیلاتین، ثاني أكسید التیتانیوم (E171)، إندیجوتین (E132)، الأزرق اللامعFCF</p><p dir="RTL">(E133)، والحبر الأبیض.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یحتوي حبر الطباعة على: الحبر الأبیض، صمغ اللك، ثاني أوكسید التیتانیوم (E171)، سیمیثیكون، غلیكول البروبیلین (E1520) وھیدروكسید الأمونیوم (E527).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما ھو شكل إمنوفید وما ھي محتویات العلبة</strong>&nbsp;</p><p dir="RTL">إمنوفید 1 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أصفر غیر شفاف، مكتوب علیھا&ldquo;POML 1 mg&rdquo; .&nbsp;</p><p dir="RTL">إمنوفید 2 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم برتقالي غیر شفاف، مكتوب علیھا&ldquo;POML 2 mg&rdquo; .</p><p dir="RTL">إمنوفید 3 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أخضر غیر شفاف، مكتوب علیھا&ldquo;POML 3 mg&rdquo; .</p><p dir="RTL">إمنوفید 4 ملغم كبسولة صلبة: غطاء أزرق داكن غیر شفاف وجسم أزرق غیر شفاف، مكتوب علیھا&ldquo;POML 4 mg&rdquo; .</p><p>&nbsp;</p><p dir="RTL">كل علبة تحتوي على 21 كبسولة (3 نفطات 7 x كبسولات).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="LTR"><strong>&nbsp; </strong>&nbsp;<strong>الشركة المالكة لحق التسویق</strong></p><p dir="LTR">&nbsp;</p><p>Bristol-Myers Squibb Pharma EEIG&nbsp;</p><p>Plaza 254</p><p>Blanchardstown Corporate Park 2</p><p>Dublin 15, D15 T867</p><p>Ireland</p><p dir="LTR"><strong>&nbsp; </strong>Celgene International Sarl, Boudry, Switzerland<strong> :</strong><strong>المصّنّعّ</strong></p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على ھذه النشرة بتاریخ اغسطس 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imnovid 1 mg hard capsules Imnovid 2 mg hard capsules Imnovid 3 mg hard capsules Imnovid 4 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imnovid 1 mg hard capsules
Each hard capsule contains 1 mg of pomalidomide.
Imnovid 2 mg hard capsules
Each hard capsule contains 2 mg of pomalidomide.
Imnovid 3 mg hard capsules
Each hard capsule contains 3 mg of pomalidomide.
Imnovid 4 mg hard capsules
Each hard capsule contains 4 mg of pomalidomide. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.
Imnovid 1 mg hard capsule:
Dark blue opaque cap and yellow opaque body, imprinted “POML” in white ink and “1 mg” in black ink, size 3 gelatin hard capsule.
Imnovid 2 mg hard capsules
Dark blue opaque cap and orange opaque body, imprinted “POML 2 mg” in white ink, size 1 gelatin hard capsule.
Imnovid 3 mg hard capsules
Dark blue opaque cap and green opaque body, imprinted “POML 3 mg” in white ink, size 1 gelatin hard capsule.
Imnovid 4 mg hard capsules
Dark blue opaque cap and blue opaque body, imprinted “POML 4 mg” in white ink, size 1 gelatin hard capsule.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.</p><p>Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment must be initiated and monitored under the supervision of physicians experienced in the management of multiple myeloma.</p><p>&nbsp;</p><p>Dosing is continued or modified based upon clinical and laboratory findings (see section 4.4). <u>Posology</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>&nbsp;</p><p>The recommended starting dose of Imnovid is 4 mg orally once daily on Days 1 to 14 of repeated 21-day cycles.</p><p>&nbsp;</p><p>Pomalidomide is administered in combination with bortezomib and dexamethasone, as shown in Table 1. The recommended starting dose of bortezomib is 1.3 mg/m<sup>2</sup> intravenous or subcutaneous once daily, on the days shown in Table 1. The recommended dose of dexamethasone is 20 mg orally once daily, on the days shown in Table 1.</p><p>&nbsp;</p><p>Treatment with pomalidomide combined with bortezomib and dexamethasone should be given until disease progression or until unacceptable toxicity occurs.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 1. Recommended dosing scheme for Imnovid in combination with bortezomib and dexamethasone</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Cycle 1-8</p></td><td colspan="21" style="vertical-align:top"><p>Day (of 21-day cycle)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Pomalidomide (4 mg)</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone (20 mg) *</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Cycle 9 onwards</p></td><td colspan="21" style="vertical-align:top"><p>Day (of 21-day cycle)</p></td></tr><tr><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Pomalidomide (4 mg)</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bortezomib (1.3 mg/m<sup>2</sup>)</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dexamethasone (20 mg) *</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&bull;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*&nbsp; For patients &gt; 75 years of age, see Special populations.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Pomalidomide dose modification or interruption</u></em></p><p>To initiate a new cycle of pomalidomide, the neutrophil count must be &sup3; 1 x 10<sup>9</sup>/l and the platelet count must be &sup3; 50 x 10<sup>9</sup>/l.</p><p>&nbsp;</p><p>Instructions on dose interruptions or reductions for pomalidomide related adverse reactions are outlined in the Table 2 and dose levels are defined in Table 3 below:</p><p>&nbsp;</p><p>Table 2. Pomalidomide dose modification instructions<sup>&infin;</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Dose modification</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Neutropenia</u></strong>*</p><p>ANC** &lt; 0.5 x 10<sup>9</sup>/l or febrile neutropenia (fever &ge;38.5&deg;C and ANC &lt;1 x 10<sup>9</sup>/l)</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
   o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
   stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1034" type="#_x0000_t75" style='width:220.5pt;
   height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>ANC return to &ge; 1 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt pomalidomide treatment for remainder of cycle. Follow CBC*** weekly.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1033" type="#_x0000_t75"
   style='width:220.5pt;height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>Resume pomalidomide treatment at one dose level lower than previous dose.</p></td></tr><tr><td style="vertical-align:top"><p>For each subsequent drop &lt; 0.5 x 10<sup>9</sup>/l</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="image4.png" o:spid="_x0000_i1032"
   type="#_x0000_t75" style='width:220.5pt;height:.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image005.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>ANC return to &ge; 1 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt pomalidomide treatment.</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="image5.png" o:spid="_x0000_i1031"
   type="#_x0000_t75" style='width:220.5pt;height:.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image006.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image007.gif" /></p><p>Resume pomalidomide treatment at one dose level lower than the previous dose.</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Thrombocytopenia</u></strong></p><p>Platelet count &lt; 25 x 10<sup>9</sup>/l</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1030" type="#_x0000_t75"
   style='width:220.5pt;height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Platelet count return to &ge; 50 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt pomalidomide treatment for remainder of cycle. Follow CBC*** weekly.</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1029" type="#_x0000_t75"
   style='width:220.5pt;height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>Resume pomalidomide treatment at one dose level lower than previous dose.</p></td></tr><tr><td style="vertical-align:top"><p>For each subsequent drop &lt; 25 x 10<sup>9</sup>/l</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1028" type="#_x0000_t75"
   style='width:220.5pt;height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Platelet count return to &ge; 50 x 10<sup>9</sup>/l</p></td><td style="vertical-align:top"><p>Interrupt pomalidomide treatment.</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="_x0000_i1027" type="#_x0000_t75"
   style='width:220.5pt;height:.75pt;visibility:visible;mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>Resume pomalidomide treatment at one dose level lower than the previous dose.</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Rash</u></strong></p><p>Rash = Grade 2-3</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="image2.png" o:spid="_x0000_i1026"
   type="#_x0000_t75" style='width:220.5pt;height:.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>Rash = Grade 4 or blistering (including angioedema, anaphylactic reaction, exfoliative or bullous rash or if Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinophilia and Systemic</p><p>Symptoms (DRESS) is suspected)</p></td><td style="vertical-align:top"><p>Consider dose interruption or discontinuation of pomalidomide treatment.</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:shape id="image3.png" o:spid="_x0000_i1025"
   type="#_x0000_t75" style='width:220.5pt;height:.75pt;visibility:visible;
   mso-wrap-style:square'>
   <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.png"
    o:title=""/>
  </v:shape><![endif]--><img width="294" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image004.gif" /></p><p>Permanently discontinue treatment (see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Other</u></strong></p><p>Other &ge; Grade 3 pomalidomide-related adverse events</p></td><td style="vertical-align:top"><p>Interrupt pomalidomide treatment for remainder of cycle. Resume at one dose level lower than previous dose at next cycle (adverse event must be resolved or improved to &le; Grade 2 before restarting dosing).</p></td></tr></tbody></table><p><strong><sup>&infin;</sup></strong><strong> </strong>Dose modification instructions in this table are applicable to pomalidomide in combination with bortezomib and dexamethasone and to pomalidomide in combination with dexamethasone.</p><p>*In case of neutropenia, the physician should consider the use of growth factors. **ANC &ndash; Absolute Neutrophil Count; ***CBC &ndash; Complete Blood Count.</p><p>&nbsp;</p><p>Table 3. Pomalidomide dose reduction&infin;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose level</strong></p></td><td style="vertical-align:top"><p><strong>Oral pomalidomide dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting dose</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose level</strong></p></td><td style="vertical-align:top"><p><strong>Oral pomalidomide dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dose level -1</p></td><td style="vertical-align:top"><p>3 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -2</p></td><td style="vertical-align:top"><p>2 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose level -3</p></td><td style="vertical-align:top"><p>1 mg</p></td></tr></tbody></table><p><strong><sup>&infin;</sup></strong>Dose reduction in this table is applicable to pomalidomide in combination with bortezomib and dexamethasone and to pomalidomide in combination with dexamethasone.</p><p>&nbsp;</p><p>If adverse reactions occur after dose reductions to 1 mg, then the medicinal product should be discontinued<em>.</em></p><p><em>&nbsp;</em></p><p><u>Strong CYP1A2 inhibitors</u></p><p>If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide by 50% (see sections 4.5 and 5.2).</p><p>&nbsp;</p><p><em>Bortezomib dose modification or interruption</em></p><p>For instructions on dose interruptions or reductions for bortezomib related adverse reactions, physicians should refer to bortezomib Summary of Product Characteristics (SmPC).</p><p>&nbsp;</p><p><em>Dexamethasone dose modification or interruption</em></p><p>Instructions on dose interruptions or reductions for low-dose dexamethasone related adverse reactions are outlined in Tables 4 and 5 below. However, dose interruption or resumption decisions are at the physician&rsquo;s discretion per Summary of Product Characteristics (SmPC).</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="image6.png"
 o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:66.25pt;margin-top:93.2pt;width:478.8pt;height:.5pt;
 z-index:-17331200;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image008.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="638" height="1" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image009.gif" />Table 4. Dexamethasone dose modification instructions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia = Grade 1-2</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Dyspepsia &ge; Grade 3</p></td><td style="vertical-align:top"><p>Maintain dose and treat with histamine (H2) blockers or equivalent. Decrease by one dose level if symptoms persist.</p><p>Interrupt dose until symptoms are controlled. Add H2 blocker or equivalent and resume at one dose level lower than previous dose.</p></td></tr><tr><td style="vertical-align:top"><p>Oedema &ge; Grade 3</p></td><td style="vertical-align:top"><p>Use diuretics as needed and decrease dose by one dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Confusion or mood alteration &ge; Grade 2</p></td><td style="vertical-align:top"><p>Interrupt dose until symptoms resolve. Resume at one dose level lower than previous dose.</p></td></tr><tr><td style="vertical-align:top"><p>Muscle weakness &ge; Grade 2</p></td><td style="vertical-align:top"><p>Interrupt dose until muscle weakness &le; Grade 1.</p><p>Resume at one dose level lower than previous dose.</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Toxicity</strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia &ge; Grade 3</p></td><td style="vertical-align:top"><p>Decrease dose by one dose level. Treat with insulin or oral hypoglycaemic agents as needed.</p></td></tr><tr><td style="vertical-align:top"><p>Acute pancreatitis</p></td><td style="vertical-align:top"><p>Discontinue dexamethasone from treatment regimen.</p></td></tr><tr><td style="vertical-align:top"><p>Other &ge; Grade 3 dexamethasone-related adverse events</p></td><td style="vertical-align:top"><p>Stop dexamethasone dosing until the adverse event resolves to &le; Grade 2. Resume at one dose level lower than previous dose.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>If recovery from toxicities is prolonged beyond 14 days, then the dose of dexamethasone will be resumed at one dose level lower than the previous dose.</p><p>&nbsp;</p><p>Table 5. Dexamethasone dose reduction</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Dose Level</strong></p></td><td style="vertical-align:top"><p><strong>&le; 75 years old</strong></p><p><strong>Dose (Cycle 1-8: Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21-day cycle</strong></p><p><strong>Cycle &ge; 9: Days 1, 2, 8, 9 of a 21-day cycle)</strong></p></td><td style="vertical-align:top"><p><strong>&gt; 75 years old</strong></p><p><strong>Dose (Cycle 1-8: Days 1, 2, 4, 5, 8, 9,</strong></p><p><strong>11, 12 of a 21-day cycle</strong></p><p><strong>Cycle &ge; 9: Days 1, 2, 8, 9 of a 21-day cycle)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting Dose</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose Level -1</p></td><td style="vertical-align:top"><p>12 mg</p></td><td style="vertical-align:top"><p>6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose Level -2</p></td><td style="vertical-align:top"><p>8 mg</p></td><td style="vertical-align:top"><p>4 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Dexamethasone should be discontinued if the patient is unable to tolerate 8 mg if &le; 75 years old or 4 mg if <strong>&gt; </strong>75 years old.</p><p>&nbsp;</p><p>In case of permanent discontinuation of any component of the treatment regimen, continuation of the remaining medicinal products is at the physician&rsquo;s discretion.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p>The recommended starting dose of Imnovid is 4 mg orally once daily on Days 1 to 21 of each 28-day cycle.</p><p>&nbsp;</p><p>The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28- day cycle.</p><p>&nbsp;</p><p>Treatment with pomalidomide combined with dexamethasone should be given until disease progression or until unacceptable toxicity occurs.</p><p>&nbsp;</p><p><em>Pomalidomide dose modification or interruption</em></p><p>Instructions for dose interruptions or reductions for pomalidomide related adverse reactions are outlined in Table 2 and 3.</p><p>&nbsp;</p><p><em>Dexamethasone dose modification or interruption</em></p><p>Instructions for dose modification for dexamethasone related adverse reactions are outlined in Table 4. Instructions for dose reduction for dexamethasone related adverse reactions are outlined in Table 6 below. However, dose interruption / resumption decisions are at physician&rsquo;s discretion per the current Summary of Product Characteristics (SmPC).</p><p>&nbsp;</p><p>Table 6. Dexamethasone dose reduction</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dose Level</strong></p></td><td style="vertical-align:top"><p><strong>&le; 75 years old</strong></p><p><strong>Days 1, 8, 15 and 22 of each 28-day cycle</strong></p></td><td style="vertical-align:top"><p><strong>&gt; 75 years old</strong></p><p><strong>Days 1, 8, 15 and 22 of each 28-day cycle</strong></p></td></tr><tr><td style="vertical-align:top"><p>Starting Dose</p></td><td style="vertical-align:top"><p>40 mg</p></td><td style="vertical-align:top"><p>20 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose Level -1</p></td><td style="vertical-align:top"><p>20 mg</p></td><td style="vertical-align:top"><p>12 mg</p></td></tr><tr><td style="vertical-align:top"><p>Dose Level -2</p></td><td style="vertical-align:top"><p>10mg</p></td><td style="vertical-align:top"><p>8 mg</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Dexamethasone should be discontinued if the patient is unable to tolerate 10 mg if &le; 75 years old or 8 mg if <strong>&gt; </strong>75 years old.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>No dose adjustment is required for pomalidomide.</p><p>For information on bortezomib given in combination with Imnovid, refer to the respective current SmPC. For patients &gt;75 years of age, the starting dose of dexamethasone is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For Cycles 1 to 8: 10 mg once daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For Cycles 9 and onwards: 10 mg once daily on Days 1, 2, 8 and 9 of each 21-day cycle.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p>No dose adjustment is required for pomalidomide.</p><p>&nbsp;</p><p>For patients &gt; 75 years of age, the starting dose of dexamethasone is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 mg once daily on days 1, 8, 15 and 22 of each 28-day cycle.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Patients with serum total bilirubin &gt; 1.5 x ULN (upper limit of normal range) were excluded from clinical studies. Hepatic impairment has a modest effect on the pharmacokinetics of pomalidomide (see</p><p>section 5.2). No adjustment of the starting dose of pomalidomide is required for patients with hepatic impairment as defined by the Child-Pugh criteria. However, patients with hepatic impairment should be carefully monitored for adverse reactions and dose reduction or interruption of pomalidomide should be used as needed.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>No dose adjustment of pomalidomide is required for patients with renal impairment. On haemodialysis days, patients should take their pomalidomide dose following haemodialysis.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Outside its authorised indications, pomalidomide has been studied in children aged 4 to 18 years with recurent or progressive brain tumours, however the results of studies did not allow to conclude that the benefits of such use outweigh the risks. Currently available data are described in section 4.8, 5.1 and 5.2 There is no relevant use of pomalidomide in children aged 0-17 years for the indication of multiple myeloma.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>Imnovid hard capsules should be taken orally at the same time each day. The capsules should not be opened, broken or chewed (see section 6.6). The capsules should be swallowed whole, preferably with water, with or without food. If the patient forgets to take a dose of pomalidomide on one day, then the patient should take the normal prescribed dose as scheduled on the next day. Patients should not adjust the dose to make up for a missing dose on previous days.</p><p>&nbsp;</p><p>It is recommended to press only on one end of the capsule to remove it from the blister thereby reducing the risk of capsule deformation or breakage.</p><p>&nbsp;</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Pregnancy.
-	Women of childbearing potential, unless all the conditions of the i-SECURE (Pregnancy •	Prevention Programme) are met (see sections 4.4 and 4.6).
-	Male patients unable to follow or comply with the required contraceptive measures (see section
•	4.4).
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teratogenicity</p><p>Pomalidomide must not be taken during pregnancy, since a teratogenic effect is expected. Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogen that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis (see section 5.3).</p><p>The conditions of the Pregnancy Prevention Programme must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.</p><p>Criteria for women of non-childbearing potential</p><p>A female patient or a female partner of a male patient is considered of non-childbearing potential if she meets at least one of the following criteria:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age &ge; 50 years and naturally amenorrhoeic for &ge; 1 year (amenorrhoea following cancer therapy or during breast-feeding does not rule out childbearing potential)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Premature ovarian failure confirmed by a specialist gynaecologist &nbsp;&nbsp; Previous bilateral salpingo-oophorectomy, or hysterectomy &nbsp;&nbsp; XY genotype, Turner syndrome, uterine agenesis.</p><p>Counselling</p><p>For women of childbearing potential, pomalidomide is contraindicated unless all of the following are met:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the expected teratogenic risk to the unborn child</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need for effective contraception, without interruption, at least 4 weeks before starting treatment, throughout the entire duration of treatment, and at least 4 weeks after the end of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Even if a woman of childbearing potential has amenorrhoea she must follow all the advice on effective contraception</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She should be capable of complying with effective contraceptive measures</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need to commence the treatment as soon as pomalidomide is dispensed following a negative pregnancy test</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She understands the need and accepts to undergo pregnancy testing at least every 4 weeks except in case of confirmed tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; She acknowledges that she understands the hazards and necessary precautions associated with the use of pomalidomide.</p><p>The prescriber must ensure that for women of childbearing potential:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient has acknowledged the aforementioned conditions.</p><p>For male patients taking pomalidomide, pharmacokinetic data has demonstrated that pomalidomide is present in human semen during treatment. As a precaution, and taking into account special populations with potentially prolonged elimination time such as hepatic impairment, all male patients taking pomalidomide must meet the following conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands the expected teratogenic risk if engaged in sexual activity with a pregnant woman or a woman of childbearing potential</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception, throughout treatment duration, during dose interruption and for 7 days after dose interruptions and/or cessation of treatment. This includes vasectomised males who should wear a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential as seminal fluid may still contain pomalidomide in the absence of spermatozoa.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He understands that if his female partner becomes pregnant whilst he is taking pomalidomide or 7 days after he has stopped taking pomalidomide, he should inform his treating physician immediately and that it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice.</p><p>Contraception</p><p>Women of childbearing potential must use at least one effective method of contraception for at least 4 weeks before therapy, during therapy, and until at least 4 weeks after pomalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred to an appropriately trained health care professional for contraceptive advice in order that contraception can be initiated.</p><p>The following can be considered to be examples of suitable methods of contraception:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Implant</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Levonorgestrel-releasing intrauterine system</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medroxyprogesterone acetate depot</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tubal sterilisation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ovulation inhibitory progesterone-only pills (i.e. desogestrel)</p><p>Because of the increased risk of venous thromboembolism in patients with multiple myeloma taking pomalidomide and dexamethasone, combined oral contraceptive pills are not recommended (see also section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective methods listed above. The risk of venous thromboembolism continues for 4-6 weeks after discontinuing combined oral contraception. The efficacy of contraceptive steroids may be reduced during cotreatment with dexamethasone (see section 4.5).</p><p>Implants and levonorgestrel-releasing intrauterine systems are associated with an increased risk of infection at the time of insertion and irregular vaginal bleeding. Prophylactic antibiotics should be considered particularly in patients with neutropenia.</p><p>Insertion of copper-releasing intrauterine devices is not recommended due to the potential risks of infection at the time of insertion and menstrual blood loss which may compromise patients with severe neutropenia or severe thrombocytopenia.</p><p>Pregnancy testing</p><p>According to local practice, medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/mL must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of pomalidomide to women of childbearing potential should occur within 7 days of the prescription.</p><p>Prior to starting treatment</p><p>A medically supervised pregnancy test should be performed during the consultation, when pomalidomide is prescribed, or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with pomalidomide.</p><p>Follow-up and end of treatment</p><p>A medically supervised pregnancy test should be repeated at least every 4 weeks, including at least 4 weeks after the end of treatment, except in the case of confirmed tubal sterilisation. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.</p><p>Additional precautions</p><p>Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.</p><p>Patients should not donate blood, semen or sperm during treatment (including during dose interruptions) and for 7 days following discontinuation of pomalidomide.</p><p>Educational materials, prescribing and dispensing restrictions</p><p>In order to assist patients in avoiding foetal exposure to pomalidomide, the Marketing Authorisation Holder will provide educational material to health care professionals to reinforce the warnings about the expected teratogenicity of pomalidomide, to provide advice on contraception before therapy is started, and to provide guidance on the need for pregnancy testing. The prescriber must inform the patient about the expected teratogenic risk and the strict pregnancy prevention measures as specified in the Pregnancy Prevention Programme and provide patients with appropriate patient educational brochure, patient card and/or equivalent tool in accordance with the national implemented patient card system. A national controlled distribution system has been implemented in collaboration with each National Competent Authority. The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and /or dispensing controls, and the collection of detailed data relating to the indication in order to monitor the off-label use within the national territory. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of pomalidomide to women of childbearing potential should occur within 7 days of the prescription and following a medically supervised negative pregnancy test result. Prescriptions for women of childbearing potential can be for a maximum duration of 4 weeks, and prescriptions for all other patients can be for a maximum duration of 12 weeks.</p><p>Haematological events</p><p>Neutropenia was the most frequently reported Grade 3 or 4 haematological adverse reaction in patients with relapsed/refractory multiple myeloma, followed by anaemia and thrombocytopenia. Patients should be monitored for haematological adverse reactions, especially neutropenia. Patients should be advised to report febrile episodes promptly. Physicians should observe patients for signs of bleeding including epistaxes, especially with use of concomitant medicinal products known to increase the risk of bleeding (see section 4.8). Complete blood counts should be monitored at baseline, weekly for the first 8 weeks and monthly thereafter. A dose modification may be required (see section 4.2). Patients may require use of blood product support and /or growth factors.</p><p>Thromboembolic events</p><p>Patients receiving pomalidomide either in combination with bortezomib and dexamethasone or in combination with dexamethasone have developed venous thromboembolic events (predominantly deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and cerebrovascular accident). Patients with known risk factors for thromboembolism &ndash; including prior thrombosis &ndash; should be closely monitored. Action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling. Anti-coagulation therapy (unless contraindicated) is recommended, (such as acetylsalicylic acid, warfarin, heparin or clopidogrel), especially in patients with additional thrombotic risk factors. A decision to take prophylactic measures should be made after a careful assessment of the individual patient&rsquo;s underlying risk factors. In clinical studies, patients received prophylactic acetylsalicylic acid or alternative anti-thrombotic therapy. The use of erythropoietic agents carries a risk of thrombotic events including thromboembolism. Therefore, erythropoietic agents, as well as other agents that may increase the risk of thromboembolic events, should be used with caution.</p><p>Peripheral neuropathy</p><p>Patients with ongoing &ge; Grade 2 peripheral neuropathy were excluded from clinical studies with pomalidomide. Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide.</p><p>Significant cardiac dysfunction</p><p>Patients with significant cardiac dysfunction (congestive heart failure [NY Heart Association Class III or IV]; myocardial infarction within 12 months of starting study; unstable or poorly controlled angina pectoris) were excluded from clinical studies with pomalidomide. Cardiac events, including congestive cardiac failure, pulmonary oedema and atrial fibrillation (see section 4.8), have been reported, mainly in patients with pre-existing cardiac disease or cardiac risk factors. Appropriate caution should be exercised when considering the treatment of such patients with pomalidomide, including periodic monitoring for signs or symptoms of cardiac events.</p><p>Tumour lysis syndrome</p><p>Patients at greatest risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.</p><p>Second primary malignancies</p><p>Second primary malignancies, such as non-melanoma skin cancer, have been reported in patients receiving pomalidomide (see section 4.8). Physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of second primary malignancies and institute treatment as indicated.</p><p>Allergic reaction and severe skin reactions</p><p>Angioedema and severe dermatologic reactions including SJS, TEN and DRESS have been reported with the use of pomalidomide (see section 4.8). Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Pomalidomide must be discontinued for exfoliative or bullous rash, or if SJS, TEN or DRESS is suspected, and should not be resumed following discontinuation for these reactions. Patients with a prior history of serious allergic reactions associated with thalidomide or lenalidomide were excluded from clinical studies. Such patients may be at higher risk of hypersensitivity reactions and should not receive pomalidomide. Pomalidomide interruption or discontinuation should be considered for Grade 2-3 skin rash. Pomalidomide must be discontinued permanently for angioedema.</p><p>Dizziness and confusion</p><p>Dizziness and confusional state have been reported with pomalidomide. Patients must avoid situations where dizziness or confusion may be a problem and not to take other medicinal products that may cause dizziness or confusion without first seeking medical advice.</p><p>Interstitial lung disease (ILD)</p><p>ILD and related events, including cases of pneumonitis, have been observed with pomalidomide. Careful assessment of patients with an acute onset or unexplained worsening of pulmonary symptoms should be performed to exclude ILD. Pomalidomide should be interrupted pending investigation of these symptoms and if ILD is confirmed, appropriate treatment should be initiated. Pomalidomide should only be resumed after a thorough evaluation of the benefits and the risks.</p><p>Hepatic disorders</p><p>Markedly elevated levels of alanine aminotransferase and bilirubin have been observed in patients treated with pomalidomide (see section 4.8). There have also been cases of hepatitis that resulted in discontinuation of pomalidomide. Regular monitoring of liver function is recommended for the first 6 months of treatment with pomalidomide and as clinically indicated thereafter.</p><p>Infections</p><p>Reactivation of hepatitis B has been reported rarely in patients receiving pomalidomide in combination with dexamethasone who have previously been infected with the hepatitis B virus (HBV). Some of these cases have progressed to acute hepatic failure, resulting in discontinuation of pomalidomide. Hepatitis B virus status should be established before initiating treatment with pomalidomide. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when pomalidomide in combination with dexamethasone is used in patients previously infected with HBV, including patients who are anti-HBc positive but HBsAg negative. These patients should be closely monitored for signs and symptoms of active HBV infection throughout therapy.</p><p>Sodium content</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, i.e. essentially &lsquo;sodium-free&rsquo;.</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p><p>Progressive multifocal leukoencephalopathy (PML)<br />Cases of progressive multifocal<br />leukoencephalopathy, including fatal cases, have<br />been reported with pomalidomide. PML was<br />reported several months to several years after<br />starting the treatment with pomalidomide. Cases<br />have generally been reported in patients taking<br />concomitant dexamethasone or prior treatment<br />with other immunosuppressive chemotherapy.<br />Physicians should monitor patients at regular</p><p>intervals and should consider PML in the<br />differential diagnosis in patients with new or<br />worsening neurological symptoms, cognitive or<br />behavioural signs or symptoms. Patients should<br />also be advised to inform their partner or<br />caregivers about their treatment, since they may<br />notice symptoms that the patient is not aware of.<br />The evaluation for PML should be based on<br />neurological examination, magnetic resonance<br />imaging of the brain, and cerebrospinal fluid<br />analysis for JC virus (JCV) DNA by polymerase<br />chain reaction (PCR) or a brain biopsy with<br />testing for JCV. A negative JCV PCR does not<br />exclude PML. Additional follow-up and<br />evaluation may be warranted if no alternative<br />diagnosis can be established.<br />If PML is suspected, further dosing must be<br />suspended until PML has been excluded. If PML<br />is confirmed, pomalidomide must be<br />permanently discontinued.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of pomalidomide on other medicinal products</p><p>Pomalidomide is not anticipated to cause clinically relevant pharmacokinetic drug-drug interactions due to P450 isoenzyme inhibition or induction or transporter inhibition when co-administered with substrates of these enzymes or transporters. The potential for such drug-drug interactions, including the potential impact of pomalidomide on the pharmacokinetics of combined oral contraceptives, has not been evaluated clinically (see section 4.4 Teratogenicity).</p><p>Effect of other medicinal products on pomalidomide</p><p>Pomalidomide is partly metabolised by CYP1A2 and CYP3A4/5. It is also a substrate for P-glycoprotein. Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide. Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to</p><p>124%] compared to pomalidomide plus ketoconazole. In a second study to evaluate the contribution of a</p><p>CYP1A2 inhibitor alone to metabolism changes, co-administration of fluvoxamine alone with pomalidomide increased mean exposure to pomalidomide by 125% with a 90% confidence interval [98% to 157%] compared to pomalidomide alone. If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide by 50%.</p><p>Dexamethasone</p><p>Co-administration of multiple doses of up to 4 mg pomalidomide with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of several CYP enzymes including CYP3A) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.</p><p>The effect of dexamethasone on warfarin is unknown. Close monitoring of warfarin concentration is advised during treatment.</p><p>For information on other medicinal products given in combination with Imnovid, refer to the respective current SmPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential / Contraception in males and females</p><p>Women of childbearing potential should use effective method of contraception. If pregnancy occurs in a woman treated with pomalidomide, treatment must be stopped and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice. If pregnancy occurs in a partner of a male patient taking pomalidomide, it is recommended to refer the female partner to a physician specialised or experienced in teratology for evaluation and advice. Pomalidomide is present in human semen. As a precaution, all male patients taking pomalidomide should use condoms throughout treatment duration, during dose interruption and for 7 days after cessation of treatment if their partner is pregnant or of childbearing potential and has no contraception (see sections 4.3 and 4.4).</p><p>Pregnancy</p><p>A teratogenic effect of pomalidomide in humans is expected. Pomalidomide is contraindicated during pregnancy and in women of childbearing potential, except when all the conditions for pregnancy prevention have been met, see section 4.3 and section 4.4.</p><p>Breast-feeding</p><p>It is unknown whether pomalidomide is excreted in human milk. Pomalidomide was detected in milk of lactating rats following administration to the mother. Because of the potential for adverse reactions in breastfed infants from pomalidomide, a decision must be made whether to discontinue breast-feeding or to discontinue the medicinal product, taking into account the benefit of breast-feeding for the child and the benefit of the therapy for the woman.</p><p>Fertility</p><p>Pomalidomide was found to impact negatively on fertility and be teratogenic in animals. Pomalidomide crossed the placenta and was detected in foetal blood following administration to pregnant rabbits, see section 5.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pomalidomide has minor or moderate influence on the ability to drive and use machines. Fatigue, depressed level of consciousness, confusion, and dizziness have been reported with the use of pomalidomide. If affected, patients should be instructed not to drive cars, use machines or perform hazardous tasks while being treated with pomalidomide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>The most commonly reported blood and lymphatic system disorders were neutropenia (46.8%), thrombocytopenia (36.7%) and anaemia (28.4%). The most frequently reported adverse reaction was peripheral sensory neuropathy (47.8%). The most commonly reported Grade 3 or 4 adverse reactions were blood and lymphatic system disorders including neutropenia (41.7%), thrombocytopenia (27.3%) and anaemia (14.0%). The most commonly reported serious adverse reaction was pneumonia (11.5%). Other serious adverse reactions reported included pyrexia (4.0%), lower respiratory tract infection (2.9%), pulmonary embolism (2.9%), influenza (2.9%), and acute kidney injury (2.9%).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p>The most commonly reported adverse reactions in clinical studies have been blood and lymphatic system disorders including anaemia (45.7%), neutropenia (45.3%) and thrombocytopenia (27%); in general disorders and administration site conditions including fatigue (28.3%), pyrexia (21%) and oedema peripheral (13%); and in infections and infestations including pneumonia (10.7%). Peripheral neuropathy adverse reactions were reported in 12.3% of patients and venous embolic or thrombotic (VTE) adverse reactions were reported in 3.3% of patients. The most commonly reported Grade 3 or 4 adverse reactions were in the blood and lymphatic system disorders including neutropenia (41.7%), anaemia (27%) and thrombocytopenia (20.7%); in infections and infestations including pneumonia (9%); and in general disorders and administration site conditions including fatigue (4.7%), pyrexia (3%) and oedema peripheral (1.3%). The most commonly reported serious adverse reaction was pneumonia (9.3%). Other serious adverse reactions reported included febrile neutropenia (4.0%), neutropenia (2.0%), thrombocytopenia (1.7%) and VTE adverse reactions (1.7 %).</p><p>&nbsp;</p><p>Adverse reactions tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>In randomised study CC-4047-MM-007, 278 patients received pomalidomide, bortezomib and dexamethasone (Pom+Btz+Dex arm). See section 4.2 for dosing information.</p><p>&nbsp;</p><p>The adverse reactions observed in patients treated with pomalidomide in combination with bortezomib and dexamethasone are listed in Table 7 by system organ class (SOC) and frequency for all adverse reactions and for Grade 3 or 4 adverse reactions.</p><p>&nbsp;</p><p>Frequencies for Pom+Btz+Dex (any grade) are defined in accordance with current guidance, as: very</p><p>common (&ge;1/10), common (&ge;1/100 to &lt;1/10); and uncommon (&ge;1/1,000 to &lt;1/100).</p><p>&nbsp;</p><p>Table 7. All Adverse Reactions (ADRs) reported in clinical trial MM-007 in patients treated with pomalidomide in combination with bortezomib and dexamethasone.</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Pneumonia</p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Viral upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Septic shock</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td><td style="vertical-align:top"><p><em>Clostridium difficile </em>colitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>Bronchitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Septic shock</p></td><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Clostridium difficile </em>colitis</p></td><td style="vertical-align:top"><p>Respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Respiratory tract infection</p></td><td style="vertical-align:top"><p>Lower respiratory tract infection</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lower respiratory tract infection</p></td><td style="vertical-align:top"><p>Lung infection</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lung infection</p></td><td style="vertical-align:top"><p>Influenza</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza</p></td><td style="vertical-align:top"><p>Bronchiolitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchiolitis</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms benign,</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>malignant and</strong></p><p><strong>unspecified (incl cysts</strong></p></td><td style="vertical-align:top"><p>Basal cell carcinoma</p></td></tr><tr><td style="vertical-align:top"><p><strong>and polyps)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top"><p>Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>Lymphopenia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Hypokalaemia Hyperglycaemia</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u> </strong>Hypomagnesaemia Hypocalcaemia Hypophosphataemia Hyperkalaemia</p><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Hypokalaemia Hyperglycaemia Hypomagnaesaemia Hypocalcaemia Hypophosphataemia Hyperkalaemia Hypercalcaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Insomnia</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Depression</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Depression Insomnia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Peripheral sensory neuropathy Dizziness</p><p>Tremor</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Syncope</p><p>Peripheral sensorimotor neuropathy Paraesthesia</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Syncope</p><p>Peripheral sensory neuropathy Peripheral sensorimotor neuropathy</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u> </strong>Dizziness Tremor</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Cataract</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Cataract</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Atrial fibrillation</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Deep vein thrombosis Hypotension Hypertension</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Hypotension Hypertension</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Deep vein thrombosis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Dyspnoea Cough</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Pulmonary embolism Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Diarrhoea Vomiting Nausea Constipation</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Abdominal pain Abdominal pain upper Stomatitis</p><p>Dry mouth</p><p>Abdominal distension</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Diarrhoea Vomiting Abdominal pain Constipation</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u> </strong>Abdominal pain upper Stomatitis</p><p>Nausea</p><p>Abdominal distension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Rash</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Muscular weakness Back pain</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Bone pain Muscle spasms</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Muscular weakness Back pain</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Bone pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Acute kidney injury Chronic kidney injury</p><p>Urinary retention</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Acute kidney injury Chronic kidney injury</p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Fatigue Pyrexia</p><p>Oedema peripheral</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Non-cardiac chest pain Oedema</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Fatigue Pyrexia</p><p>Non-cardiac chest pain Oedema peripheral Oedema</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Alanine aminotransferase increased Weight decreased</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Weight decreased</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Alanine aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and</strong></p><p><strong>procedural complications</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Fall</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Fall</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p>In randomised study CC-4047-MM-003, 302 patients with relapsed and refractory multiple myeloma were exposed to 4 mg pomalidomide administered once daily for 21 days of each 28&ndash;day cycle in combination with a weekly low dose of dexamethasone.</p><p>&nbsp;</p><p>The adverse reactions observed in patients treated with pomalidomide plus dexamethasone are listed below in Table 8 by system organ class (SOC) and frequency for all adverse reactions (ADRs) and for Grade 3 or 4 adverse reactions.</p><p>&nbsp;</p><p>The frequencies of adverse reactions are those reported in the pomalidomide plus dexamethasone arm of study CC-4047-MM-003 (n = 302). Within each SOC and frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequencies are defined in accordance with current guidance, as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); and uncommon (&ge; 1/1,000 to &lt; 1/100).</p><p>Table 8. ADRs reported in clinical study MM-003 in patients treated with pomalidomide in combination with dexamethasone.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All ADRs/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Pneumonia (bacterial, viral and fungal infections, including opportunistic infections)</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u> </strong>Neutropenic sepsis Bronchopneumonia Bronchitis</p><p>Respiratory tract infection Upper respiratory tract infection Nasopharyngitis</p><p>Herpes zoster</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Neutropenic sepsis</p><p>Pneumonia (bacterial, viral and fungal infections, including opportunistic infections) Bronchopneumonia Respiratory tract infection</p><p>Upper respiratory tract infection</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u> </strong>Bronchitis Herpes zoster</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All ADRs/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Basal cell carcinoma of the skin, Squamous cell carcinoma of the skin</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Neutropenia Thrombocytopenia Leucopenia Anaemia</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Neutropenia Thrombocytopenia Anaemia</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Febrile neutropenia Leucopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u></strong></p><p>Decreased appetite</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u> </strong>Hyperkalaemia Hyponatraemia</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Hyperkalaemia Hyponatraemia</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Confusional state</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Confusional state</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Depressed level of consciousness Peripheral sensory neuropathy Dizziness</p><p>Tremor</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Depressed level of consciousness</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Peripheral sensory neuropathy Dizziness</p><p>Tremor</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Vertigo</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Deep vein thrombosis</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Deep vein thrombosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Dyspnoea Cough</p><p><strong>&nbsp;</strong></p><p><strong><u>Common</u></strong></p><p>Pulmonary embolism</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Dyspnoea</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u> </strong>Pulmonary embolism Cough</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All ADRs/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 ADRs/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Diarrhoea Nausea Constipation</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Diarrhoea Vomiting Constipation</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Vomiting</p><p>Gastrointestinal haemorrhage</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Nausea</p><p>Gastrointestinal haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Hyperbilirubinaemia</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Hyperbilirubinaemia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Rash Pruritus</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Bone pain Muscle spasms</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Bone pain</p><p><strong>&nbsp;</strong></p><p><strong><u>Uncommon</u></strong></p><p>Muscle spasms</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Renal failure Urinary retention</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Renal failure</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Pelvic pain</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Pelvic pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong><u>Very Common</u> </strong>Fatigue Pyrexia</p><p>Oedema peripheral</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Fatigue Pyrexia</p><p>Oedema peripheral</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Neutrophil count decreased White blood cell count decreased Platelet count decreased</p><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Neutrophil count decreased White blood cell count decreased Platelet count decreased</p><p>Alanine aminotransferase increased</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Tabulated list of post-marketing adverse reactions</u></p><p>&nbsp;</p><p>In addition to the above adverse reactions identified from the pivotal clinical trials, the following Table 9 is derived from data gathered from post-marketing surveillance.</p><p><u>Frequencies are defined in accordance with current guidance, as: very common (&ge; 1/10), common (&ge;</u> <u>1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) and not known (frequency cannot be determined).</u></p><p>&nbsp;</p><p>Table 9. ADRs reported in post-marketing use in patients treated with pomalidomide.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Hepatitis B reactivation</p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Hepatitis B reactivation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Pancytopenia</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Angioedema</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p><u>Hypothyroidism</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Hyperuricaemia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Tumour lysis syndrome</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>Intracranial haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cerebrovascular accident</p></td><td style="vertical-align:top"><p>Cerebrovascular accident</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intracranial haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Cardiac failure Atrial fibrillation</p><p>Myocardial infarction</p></td><td style="vertical-align:top"><p><strong><u>Common</u> </strong>Cardiac failure Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Epistaxis</p><p>Interstitial lung disease</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Epistaxis</p><p>Interstitial lung disease</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Drug Reaction with Eosinophilia and Systemic Symptoms</p><p>Toxic Epidermal Necrolysis Stevens-Johnson Syndrome</p></td><td style="vertical-align:top"><p><strong><u>Not Known</u></strong></p><p>Drug Reaction with Eosinophilia and Systemic Symptoms</p><p>Toxic Epidermal Necrolysis Stevens-Johnson Syndrome</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class/ Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>All Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3&minus;4 Adverse Reactions</strong></p><p><strong>/Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong><u>Common</u></strong></p><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p><strong><u>Uncommon</u></strong></p><p>Blood uric acid increased</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Teratogenicity</em></p><p>Pomalidomide is structurally related to thalidomide. Thalidomide is a known human teratogenic active substance that causes severe life-threatening birth defects. Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis (see sections 4.6</p><p>and 5.3). If pomalidomide is taken during pregnancy, a teratogenic effect of pomalidomide in humans is expected (see section 4.4).</p><p>&nbsp;</p><p><em>Neutropenia and thrombocytopenia</em></p><p>In patients receiving combination therapy with pomalidomide in clinical studies, neutropenia occurred in up to 46.8% of patients (41.7% Grade 3 or 4). Neutropenia did not lead to pomalidomide discontinuation in any patient and was infrequently serious.</p><p>&nbsp;</p><p>Febrile neutropenia (FN) was reported in 3.2-6.7% of patients and was serious in 1.8-4.0% of patients (see section 4.2 and 4.4).</p><p>&nbsp;</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, thrombocytopenia occurred in 27.0-36.7% of patients. Thrombocytopenia was Grade 3 or 4 in 20.7-27.3% of patients, led to pomalidomide discontinuation in 0.7% of patients and was serious in 0.4-1.7% of patients (see</p><p>sections 4.2 and 4.4).</p><p>&nbsp;</p><p>Neutropenia and thrombocytopenia tended to occur more frequently within the first 2 cycles of treatment with pomalidomide.</p><p>&nbsp;</p><p><em>Infection</em></p><p>Infection was the most common non haematological toxicity.</p><p>&nbsp;</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, infection occurred in 55.0-80.2% of patients (24.0-30.9% Grade 3 or 4). Upper respiratory tract infection and pneumonia were the most frequently occurring infections. Fatal infections (Grade 5) occurred in 2.7-4.0% of patients.</p><p>Infections led to pomalidomide discontinuation in 2.0-2.9% of patients.</p><p>&nbsp;</p><p><em>Thromboembolic events</em></p><p>Prophylaxis with acetylsalicylic acid (and other anticoagulants in high risk patients) was mandatory for all patients in clinical studies. Anticoagulation therapy (unless contraindicated) is recommended (see</p><p>section 4.4).</p><p>&nbsp;</p><p>In patients receiving combination therapy with pomalidomide in clinical studies, venous thromboembolic events (VTE) occurred in 3.3-11.5% of patients (1.3-5.4% Grade 3 or 4). VTE was reported as serious in 1.7-4.3% of patients, no fatal reactions were reported, and VTE was associated with pomalidomide discontinuation in up to 1.8% of patients.</p><p>&nbsp;</p><p><em>Peripheral neuropathy</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>Patients with ongoing peripheral neuropathy &ge; Grade 2 with pain within 14 days prior to randomisation were excluded from clinical trials. Peripheral neuropathy occurred in 55.4 % of patients (10.8% Grade 3; 0.7% Grade 4). Exposure-adjusted rates were comparable across treatment arms. Approximately 30% of the patients experiencing peripheral neuropathy had a history of neuropathy at baseline. Peripheral neuropathy led to discontinuation of bortezomib in approximately 12.9% of patients, pomalidomide in 1.8% and dexamethasone in 2.2 - 8.9% of patients, respectively. Refer also to the bortezomib SmPC.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p>Patients with ongoing peripheral neuropathy &ge; Grade 2 were excluded from clinical studies. Peripheral neuropathy occurred in 12.3% of patients (1.0% Grade 3 or 4). No peripheral neuropathy reactions were reported as serious, and peripheral neuropathy led to dose discontinuation in 0.3% of patients (see section 4.4).</p><p>&nbsp;</p><p><em>Haemorrhage</em></p><p>Haemorrhagic disorders have been reported with pomalidomide, especially in patients with risk factors such as concomitant medicinal products that increase susceptibility to bleeding. Haemorrhagic events have included epistaxis, intracranial haemorrhage and gastrointestinal haemorrhage.</p><p>&nbsp;</p><p><em>Allergic reactions and severe skin reactions</em></p><p>Angioedema, anaphylactic reaction and severe cutaneous reactions including SJS, TEN and DRESS have been reported with the use of pomalidomide. Patients with a history of severe rash associated with lenalidomide or thalidomide should not receive pomalidomide (see section 4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Adverse reactions reported in paediatric patients (aged 4 to 18 years) with recurrent or progressive brain tumours were consistent with the known pomalidomide safety profile in adult patients (see section 5.1).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:66.3pt;margin-top:47.65pt;width:425pt;
 height:79.4pt;z-index:15729664;mso-position-horizontal-relative:page'
 filled="f" strokeweight="1.06pt">
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>The National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table></td></tr></tbody></table><p>To report any side effect(s): Saudi Arabia:</p><p><strong>&nbsp;</strong></p><p><strong>United Arab Emirates:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:66.3pt;
  margin-top:11.25pt;width:467pt;height:121.65pt;z-index:-15727104;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight="1.06pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-left:10.15pt;line-height:12.5pt;
     mso-line-height-rule:exactly'>Pharmacovigilance<span style='letter-spacing:
     -.15pt'> </span>and<span style='letter-spacing:-.2pt'> </span>Medical<span
     style='letter-spacing:-.05pt'> </span>Device<span style='letter-spacing:
     -.05pt'> </span>Section<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:356.7pt;
     margin-bottom:0in;margin-left:10.15pt;margin-bottom:.0001pt'>P.O. Box:
     1853 Dubai<span style='letter-spacing:-2.6pt'> </span>Tel:<span
     style='letter-spacing:-.1pt'> </span>80011111<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:340.55pt;
     margin-bottom:0in;margin-left:10.15pt;margin-bottom:.0001pt;text-indent:
     -.05pt;line-height:103%'>Email: <a href="mailto:pv@mohap.gov.ae"><span
     style='color:blue'>pv@mohap.gov.ae</span></a><span style='color:blue;
     letter-spacing:-2.6pt'> </span>Drug<span style='letter-spacing:.05pt'> </span>Department<span
     style='letter-spacing:.05pt'> </span>Ministry<span style='letter-spacing:
     -.2pt'> </span>of<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:0in;margin-right:407.6pt;
     margin-bottom:0in;margin-left:10.15pt;margin-bottom:.0001pt;line-height:
     103%'>Health &amp;<span style='letter-spacing:.05pt'> </span><span
     style='letter-spacing:-.05pt'>Prevention</span><span style='letter-spacing:
     -2.6pt'> </span>Dubai<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="629" height="169" alt="Text Box: Pharmacovigilance and Medical Device Section
P.O. Box: 1853 Dubai Tel: 80011111
Email: pv@mohap.gov.ae Drug Department Ministry of
Health &amp; Prevention Dubai
" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong><em>Oman:</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;margin-left:72.25pt;
  margin-top:12.3pt;width:467.55pt;height:126.85pt;z-index:-15726592;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:1.85pt;margin-right:179.25pt;
     margin-bottom:0in;margin-left:10.4pt;margin-bottom:.0001pt;line-height:
     115%'>Department of Pharmacovigilance &amp; Drug Information<span
     style='letter-spacing:.05pt'> </span>Directorate General of Pharmaceutical
     Affairs &amp; Drug Control<span style='letter-spacing:-2.6pt'> </span>Ministry<span
     style='letter-spacing:-.05pt'> </span>of<span style='letter-spacing:.05pt'>
     </span>Health, Sultanate<span style='letter-spacing:-.05pt'> </span>of<span
     style='letter-spacing:.05pt'> </span>Oman<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:10.4pt;line-height:12.55pt;
     mso-line-height-rule:exactly'>Phone<span style='letter-spacing:-.05pt'> </span>Nos.<span
     style='letter-spacing:-.15pt'> </span>00968 22357687 /<span
     style='letter-spacing:.05pt'> </span>00968 22357686<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.0pt;margin-right:0in;margin-bottom:
     0in;margin-left:10.4pt;margin-bottom:.0001pt'>Fax: 00968 22358489<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:1.85pt;margin-right:301.0pt;
     margin-bottom:0in;margin-left:10.4pt;margin-bottom:.0001pt;line-height:
     115%'>Email: <a href="mailto:pharma-vigil@moh.gov.om"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>pharma-vigil@moh.gov.om</span></a><span
     style='letter-spacing:-2.6pt'> </span>Website<span style='letter-spacing:
     -.05pt'> </span>: <a href="http://www.moh.gov.om/"><span style='color:
     windowtext;text-decoration:none;text-underline:none'>www.moh.gov.om</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="630" height="175" alt="Text Box: Department of Pharmacovigilance &amp; Drug Information Directorate General of Pharmaceutical Affairs &amp; Drug Control Ministry of Health, Sultanate of Oman
Phone Nos. 00968 22357687 / 00968 22357686
Fax: 00968 22358489
Email: pharma-vigil@moh.gov.om Website : www.moh.gov.om
" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot; <strong><em>Other Countries:</em></strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;margin-left:66.5pt;
  margin-top:13.4pt;width:479pt;height:22.8pt;z-index:-15726080;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight="1.06pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.55pt;margin-right:0in;margin-bottom:
     0in;margin-left:10.0pt;margin-bottom:.0001pt'><b style='mso-bidi-font-weight:
     normal'><span style='color:#1E487C'>-<span style='letter-spacing:-.05pt'> </span></span></b>Please<span
     style='letter-spacing:-.15pt'> </span>contact<span style='letter-spacing:
     -.15pt'> </span>the<span style='letter-spacing:-.2pt'> </span>relevant
     competent<span style='letter-spacing:-.15pt'> </span>authority.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="646" height="36" alt="Text Box: - Please contact the relevant competent authority." src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pomalidomide doses as high as 50 mg as a single dose in healthy volunteers, and 10 mg as once-daily multiple doses in multiple myeloma patients have been studied without reported serious adverse reactions related to overdose. In studies, pomalidomide was found to be removed by haemodialysis.</p><p>In the event of overdose, supportive care is advised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, Other immunosuppressants ATC code: L04AX06 <u>Mechanism of action</u></p><p>&nbsp;</p><p>Pomalidomide has direct anti-myeloma tumoricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Specifically, pomalidomide inhibits proliferation and induces apoptosis of haematopoietic tumour cells. Additionally, pomalidomide inhibits the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergises with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumour cell apoptosis. Pomalidomide enhances T cell- and natural killer (NK) cell-mediated immunity and inhibits production of pro-inflammatory cytokines (e.g., TNF-&alpha; and IL-6) by monocytes. Pomalidomide also inhibits angiogenesis by blocking the migration and adhesion of endothelial cells.</p><p>&nbsp;</p><p>Pomalidomide binds directly to the protein cereblon (CRBN), which is part of an E3 ligase complex that includes deoxyribonucleic acid (DNA) damage-binding protein 1(DDB1), cullin 4 (CUL4), and regulator of cullins-1 (Roc1), and can inhibit the auto-ubiquitination of CRBN within the complex. E3 ubiquitin ligases are responsible for the poly-ubiquitination of a variety of substrate proteins, and may partially explain the pleiotropic cellular effects observed with pomalidomide treatment.</p><p>&nbsp;</p><p>In the presence of pomalidomide <em>in vitro</em>, substrate proteins Aiolos and Ikaros are targeted for ubiquitination and subsequent degradation leading to direct cytotoxic and immunomodulatory effects. <em>In vivo</em>, pomalidomide therapy led to reduction in the levels of Ikaros in patients with relapsed lenalidomide- refractory multiple myeloma.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with bortezomib and dexamethasone</em></p><p>The efficacy and safety of pomalidomide in combination with bortezomib and low-dose dexamethasone (Pom+Btz+LD-Dex) was compared with bortezomib and low-dose dexamethasone (Btz+LD-Dex) in a Phase III multi-centre, randomised, open-label study (CC-4047-MM-007), in previously treated adult patients with multiple myeloma, who had received at least one prior regimen, including lenalidomide and have demonstrated disease progression on or after the last therapy. A total of 559 patients were enrolled and randomised in the study: 281 in the Pom+Btz+LD-Dex arm and 278 in the Btz+LD-Dex arm. 54% of patients were male with median age for the overall population of 68 years (min, max: 27, 89 years).</p><p>Approximately 70% of patients were refractory to lenalidomide (71.2% in Pom+Btz+LD-Dex, 68.7 % in Btz+LD-Dex). Approximately 40% of patients were in 1<sup>st</sup> relapse and approximately 73% of patients received bortezomib as prior treatment.</p><p>&nbsp;</p><p>Patients in the Pom+Btz+LD-Dex arm were administered 4 mg pomalidomide orally on Days 1 to 14 of each 21-day cycle. Bortezomib (1.3 mg/m<sup>2</sup>/dose) was administered to patients in both study arms on Days 1, 4, 8 and 11 of a 21-day cycle for Cycles 1 to 8; and on Days 1 and 8 of a 21-day cycle for Cycles 9 and onwards. Low-dose dexamethasone (20 mg/day [&le; 75 years old] or 10 mg/day [&gt; 75 years old]) was administered to patients in both study arms on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle for Cycles</p><p>1 to 8; and on Days 1, 2, 8 and 9 of each subsequent 21-day cycle from Cycles 9 onwards. Doses were reduced and treatment was temporarily interrupted or stopped as needed to manage toxicity (see section 4.2).</p><p>&nbsp;</p><p>The primary efficacy endpoint was Progression Free Survival (PFS) assessed by an Independent Response Adjudication Committee (IRAC) according to the IMWG criteria using the intent to treat population (ITT). After a median follow-up of 15.9 months, median PFS time was 11.20 months (95% CI: 9.66, 13.73) in the Pom+Btz+LD-Dex arm. In the Btz+LD-Dex arm, median PFS time was 7.1 months (95% CI: 5.88, 8.48).</p><p>&nbsp;</p><p>Summary of overall efficacy data are presented in Table 10 using a cut-off date of 26 Oct 2017. Kaplan- Meier curve for PFS for the ITT population is provided in Figure 1.</p><p>&nbsp;</p><p>Table 10. Summary of overall efficacy data</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pom+Btz+LD-Dex (N = 281)</p></td><td style="vertical-align:top"><p>Btz+LD-Dex (N = 278)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS (months)</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup> time (95% CI) <sup>b</sup></p></td><td style="vertical-align:top"><p>11.20 (9.66, 13.73)</p></td><td style="vertical-align:top"><p>7.10 (5.88, 8.48)</p></td></tr><tr><td style="vertical-align:top"><p>HR <sup>c</sup> (95% CI), p-value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.61 (0.49, 0.77), &lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>ORR, n (%)</strong></p></td><td style="vertical-align:top"><p>82.2 %</p></td><td style="vertical-align:top"><p>50.0%</p></td></tr><tr><td style="vertical-align:top"><p>sCR</p></td><td style="vertical-align:top"><p>9 (3.2)</p></td><td style="vertical-align:top"><p>2 (0.7)</p></td></tr><tr><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>35 (12.5)</p></td><td style="vertical-align:top"><p>9 (3.2)</p></td></tr><tr><td style="vertical-align:top"><p>VGPR</p></td><td style="vertical-align:top"><p>104 (37.0)</p></td><td style="vertical-align:top"><p>40 (14.4)</p></td></tr><tr><td style="vertical-align:top"><p>PR</p></td><td style="vertical-align:top"><p>83 (29.5)</p></td><td style="vertical-align:top"><p>88 (31.7)</p></td></tr><tr><td style="vertical-align:top"><p>OR (95% CI) <sup>e</sup>, p-value<sup>f</sup></p></td><td colspan="2" style="vertical-align:top"><p>5.02 (3.35, 7.52), &lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>DoR (months)</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup> time (95% CI) <sup>b</sup></p></td><td style="vertical-align:top"><p>13.7 (10.94, 18.10)</p></td><td style="vertical-align:top"><p>10.94 (8.11, 14.78)</p></td></tr><tr><td style="vertical-align:top"><p>HR<sup>c</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.76 (0.56, 1.02)</p></td></tr></tbody></table><p>Btz = bortezomib; CI = Confidence interval; CR = Complete response; DoR = Duration of response; HR = Hazard Ratio; LD-Dex = low-dose dexamethasone; OR = Odds ratio; ORR = Overall response rate; PFS = Progression free survival; POM = pomalidomide; PR = Partial Response; sCR = Stringent complete response VGPR = Very good partial response.</p><p><sup>a</sup> The median is based on the Kaplan-Meier estimate.</p><p><sup>b</sup> 95% CI about the median.</p><p><sup>c</sup> Based on Cox proportional hazards model.</p><p><sup>d</sup> The p-value is based on a stratified log-rank test.</p><p><sup>e</sup> Odds ratio is for Pom+Btz+LD-Dex:Btz+LD-Dex.</p><p><sup>f</sup> The p-value is based on a CMH test, stratified by age (&lt;=75 vs &gt;75), Prior number of antimyeloma regimens (1 vs &gt;1), and Beta-2 microglobulin at screening (&lt; 3.5 mg/L versus &ge; 3.5 mg/L &mdash; &le; 5.5 mg/L versus &gt; 5.5 mg/L).</p><p>&nbsp;</p><p>The median duration of treatment was 8.8 months (12 treatment cycles) in the Pom+Btz+LD-Dex arm and 4.9 months (7 treament cycles) in the Btz+LD-Dex arm.</p><p>&nbsp;</p><p>The PFS advantage was more pronounced in patients who received only one prior line of therapy. In patients who received 1 prior antimyeloma line, median PFS time was 20.73 months (95% CI: 15.11, 27.99) in the Pom + Btz + LD-Dex arm and 11.63 months (95% CI: 7.52, 15.74) in the Btz + LD-Dex arm. A 46% risk reduction was observed with Pom + Btz + LD-Dex treatment (HR = 0.54, 95% CI: 0.36, 0.82).</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image7.jpeg" o:spid="_x0000_s1036" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:1in;margin-top:31.9pt;
  width:440.55pt;height:248.4pt;z-index:6;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="587" height="331" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image002.jpg" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Figure 1. Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population).</p><p>Data cutoff: 26 Oct 2017</p><p>&nbsp;</p><p>As per an interim analysis for Overall Survival (OS), using a cut-off of 15 September 2018 (median follow-up period of 26.2 months), median OS time from Kaplan-Meier estimates was 40.5 months for the Pom + Btz + LD-Dex arm and 30.5 months for the Btz + LD-Dex arm; HR = 0.91, 95% CI: 0.70, 1.18, with an overall event rate of 43.3%.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pomalidomide in combination with dexamethasone</em></p><p><em>&nbsp;</em></p><p>The efficacy and safety of pomalidomide in combination with dexamethasone were evaluated in a Phase III multi-centre, randomised, open-label study (CC-4047-MM-003), where pomalidomide plus low-dose dexamethasone therapy (Pom+LD-Dex) was compared to high-dose dexamethasone alone (HD-Dex) in previously treated adult patients with relapsed and refractory multiple myeloma, who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. A total of 455 patients were enrolled in the study: 302 in the Pom+LD-Dex arm and 153 in the HD-Dex arm. The majority of patients were male (59%) and white (79%); the median age for the overall population was 64 years (min, max: 35, 87 years).</p><p>&nbsp;</p><p>Patients in the Pom+LD-Dex arm were administered 4 mg pomalidomide orally on days 1 to 21 of each 28-day cycle. LD-Dex (40 mg) was administered once per day on days 1, 8, 15 and 22 of a 28-day cycle. For the HD-Dex arm, dexamethasone (40 mg) was administered once per day on days 1 through 4,</p><p>9 through 12, and 17 through 20 of a 28-day cycle. Patients &gt; 75 years of age started treatment with 20 mg dexamethasone. Treatment continued until patients had disease progression.</p><p>&nbsp;</p><p>The primary efficacy endpoint was progression free survival by International Myeloma Working Group (IMWG criteria). For the intention to treat (ITT) population, median PFS time by Independent Review Adjudication Committee (IRAC) review based on IMWG criteria was 15.7 weeks (95% CI: 13.0, 20.1) in the Pom + LD-Dex arm; the estimated 26-week event-free survival rate was 35.99% (&plusmn;3.46%). In the</p><p>&nbsp;</p><p>HD-Dex arm, median PFS time was 8.0 weeks (95% CI: 7.0, 9.0); the estimated 26-week event-free survival rate was 12.15% (&plusmn;3.63%).</p><p>&nbsp;</p><p>PFS was evaluated in several relevant subgroups: gender, race, ECOG performance status, stratification factors (age, disease population, prior anti-myeloma therapies [2, &gt; 2]), selected parameters of prognostic significance (baseline beta-2 microglobulin level, baseline albumin levels, baseline renal impairment, and cytogenetic risk), and exposure and refractoriness to prior anti-myeloma therapies. Regardless of the subgroup evaluated, PFS was generally consistent with that observed in the ITT population for both treatment groups.</p><p>&nbsp;</p><p>PFS is summarised in Table 11 for the ITT population. Kaplan-Meier curve for PFS for the ITT population is provided in Figure 2.</p><p>&nbsp;</p><p>Table 11. Progression Free Survival Time by IRAC Review Based on IMWG Criteria (Stratified Log Rank Test) (ITT Population)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Pom+LD</strong>-<strong>Dex</strong><strong> (N=302)</strong></p></td><td style="vertical-align:top"><p><strong>HD</strong>-<strong>Dex (N=153)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Progression free survival (PFS), N</p></td><td style="vertical-align:top"><p>302 (100.0)</p></td><td style="vertical-align:top"><p>153 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Censored, n (%)</p></td><td style="vertical-align:top"><p>138 (45.7)</p></td><td style="vertical-align:top"><p>50 (32.7)</p></td></tr><tr><td style="vertical-align:top"><p>Progressed/Died, n (%)</p></td><td style="vertical-align:top"><p>164 (54.3)</p></td><td style="vertical-align:top"><p>103 (67.3)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Progression Free Survival Time (weeks)</p></td></tr><tr><td style="vertical-align:top"><p>Median<sup>a</sup></p></td><td style="vertical-align:top"><p>15.7</p></td><td style="vertical-align:top"><p>8.0</p></td></tr><tr><td style="vertical-align:top"><p>Two sided 95% CI<sup>b</sup></p></td><td style="vertical-align:top"><p>[13.0, 20.1]</p></td><td style="vertical-align:top"><p>[7.0, 9.0]</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CI <sup>c</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.45 [0.35,0.59]</p></td></tr><tr><td style="vertical-align:top"><p>Log-Rank Test Two sided P-Value <sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>Note: CI=Confidence interval; IRAC=Independent Review Adjudication Committee; NE = Not Estimable.</p><p><sup>a</sup> The median is based on Kaplan-Meier estimate.</p><p><sup>b</sup> 95% confidence interval about the median progression free survival time.</p><p><sup>c</sup> Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age</p><p>(&le;75 vs &gt;75),diseases population (refractory to both lenalidomide and bortezomib vs not refractory to both active substances), and prior number of anti myeloma therapy (=2 vs &gt;2).</p><p><sup>d</sup> The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model. Data cutoff: 07 Sep 2012</p><p>&nbsp;</p><p>Figure 2. Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population)</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:107.5pt;
 margin-top:2.7pt;width:430.15pt;height:255.55pt;z-index:15732224;
 mso-position-horizontal-relative:page' coordorigin="2150,54" coordsize="8603,5111">
 <v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:2150;
  top:53;width:8603;height:5111'>
  <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image003.jpg"
   o:title=""/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1028" type="#_x0000_t202" style='position:absolute;
  left:9408;top:404;width:1061;height:464' filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:8.9pt;mso-line-height-rule:exactly'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt'>HD-DEX<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:5.05pt'><span style='font-size:8.0pt;
     mso-bidi-font-size:11.0pt'>POM+LD-DEX<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
  left:2311;top:4211;width:3455;height:731' filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:8.9pt;mso-line-height-rule:exactly'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt'>POM+LD-DEX<span
     style='letter-spacing:-.15pt'> </span>vs<span style='letter-spacing:.05pt'>
     </span>HD-DEX<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:.05pt;margin-right:54.75pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt'>Logrank p-value = &lt;
     0.001 (2-sided)<span style='letter-spacing:-1.85pt'> </span>HR (95%<span
     style='letter-spacing:-.1pt'> </span>CI)<span style='letter-spacing:-.05pt'>
     </span>0.45<span style='letter-spacing:-.05pt'> </span>(0.35,<span
     style='letter-spacing:-.05pt'> </span>0.59)<o:p></o:p></span></p>
     <p class=MsoNormal style='line-height:9.15pt;mso-line-height-rule:exactly'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt'>Events:<span
     style='letter-spacing:-.3pt'> </span>POM+LD-DEX=164/302<span
     style='letter-spacing:-.25pt'> </span>HD-DEX=103/153<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="574" height="341" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image004.gif" />1.0</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.8</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1030"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:71.4pt;margin-top:20.55pt;width:12pt;height:78.15pt;z-index:15732736;
 mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.6pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt'><span style='font-size:9.0pt;
    mso-bidi-font-size:11.0pt'>Propotion<span style='letter-spacing:-.15pt'> </span>of<span
    style='letter-spacing:-.1pt'> </span>Patients<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="20" height="108" alt="Text Box: Propotion of Patients" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image005.gif" />0.6</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.4</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.2</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.0</p><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p><p>Progression Free Survival (weeks)</p><p>Data cutoff: 07 Sep 2012</p><p>&nbsp;</p><p>Overall Survival was the key secondary study endpoint. A total of 226 (74.8%) of the Pom + LD-Dex patients and 95 (62.1%) of the HD-Dex patients were alive as of the cutoff date (07 Sep 2012). Median OS time from Kaplan-Meier estimates has not been reached for the Pom + LD-Dex, but would be expected to be at least 48 weeks, which is the lower boundary of the 95% CI. Median OS time for the HD-Dex arm was 34 weeks (95% CI: 23.4, 39.9). The 1-year event free rate was 52.6% (&plusmn; 5.72%) for the Pom + LD-Dex arm and 28.4% (&plusmn; 7.51%) for the HD-Dex arm. The difference in OS between the two treatment arms was statistically significant (p &lt; 0.001).</p><p>&nbsp;</p><p>Overall survival is summarised in Table 12 for the ITT population. Kaplan-Meier curve for OS for the ITT population is provided in Figure 3.</p><p>&nbsp;</p><p>Based on the results of both PFS and OS endpoints, the Data Monitoring Committee established for this study recommended that the study be completed and patients in the HD-Dex arm be crossed over to the Pom + LD-Dex arm.</p><p>&nbsp;</p><p>Table 12. Overall Survival: ITT Population</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Statistics</strong></p></td><td style="vertical-align:top"><p><strong>Pom+LD</strong>-<strong>Dex</strong><strong> (N=302)</strong></p></td><td style="vertical-align:top"><p><strong>HD</strong>-<strong>Dex (N=153)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>302 (100.0)</p></td><td style="vertical-align:top"><p>153 (100.0)</p></td></tr><tr><td style="vertical-align:top"><p>Censored</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>226 (74.8)</p></td><td style="vertical-align:top"><p>95 (62.1)</p></td></tr><tr><td style="vertical-align:top"><p>Died</p></td><td style="vertical-align:top"><p>n (%)</p></td><td style="vertical-align:top"><p>76 (25.2)</p></td><td style="vertical-align:top"><p>58 (37.9)</p></td></tr><tr><td style="vertical-align:top"><p>Survival Time (weeks)</p></td><td style="vertical-align:top"><p>Median<sup>a</sup></p></td><td style="vertical-align:top"><p>NE</p></td><td style="vertical-align:top"><p>34.0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Two sided 95% CI<sup>b</sup></p></td><td style="vertical-align:top"><p>[48.1, NE]</p></td><td style="vertical-align:top"><p>[23.4, 39.9]</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard Ratio (Pom+LD-Dex:HD-Dex) [Two sided 95% CI<sup>c</sup>]</p></td><td colspan="2" style="vertical-align:top"><p>0.53[0.37, 0.74]</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Log-Rank Test Two sided P-Value<sup>d</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p>Note: CI=Confidence interval. NE = Not Estimable.</p><p><sup>a</sup> The median is based on Kaplan-Meier estimate.</p><p><sup>b</sup> 95% confidence interval about the median overall survival time.</p><p><sup>c</sup> Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups.</p><p><sup>d</sup> The p-value is based on an unstratified log-rank test. Data cutoff: 07 Sep 2012</p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 3. Kaplan-Meier Curve of Overall Survival (ITT Population)</p><p><strong>&nbsp;</strong></p><p><!--[if gte vml 1]><v:group id="_x0000_s1031"
 style='position:absolute;left:0;text-align:left;margin-left:103.9pt;
 margin-top:-.15pt;width:432.15pt;height:216.9pt;z-index:15733248;
 mso-position-horizontal-relative:page' coordorigin="2078,-3" coordsize="8643,4338">
 <v:shape id="_x0000_s1032" type="#_x0000_t75" style='position:absolute;left:2078;
  top:-4;width:8643;height:4338'>
  <v:imagedata src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image006.jpg"
   o:title=""/>
 </v:shape><v:shape id="_x0000_s1033" type="#_x0000_t202" style='position:absolute;
  left:9453;top:398;width:949;height:332' filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:110%'><span style='font-size:7.0pt;
     mso-bidi-font-size:11.0pt;line-height:110%'>HD-DEX<span style='letter-spacing:
     .05pt'> </span><span style='letter-spacing:-.15pt'>POM+LD</span><span
     style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.1pt'>-DEX</span><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1034" type="#_x0000_t202" style='position:absolute;
  left:2299;top:2815;width:3298;height:1235' filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:8.9pt;mso-line-height-rule:exactly'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt'>POM+LD-DEX<span
     style='letter-spacing:-.15pt'> </span>vs<span style='letter-spacing:.05pt'>
     </span>HD-DEX<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:1.35pt;margin-right:46.9pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;line-height:115%'><span
     style='font-size:8.0pt;mso-bidi-font-size:11.0pt;line-height:115%'>Logrank
     p-value = &lt; 0.001 (2-sided)<span style='letter-spacing:-1.85pt'> </span>HR
     (95%<span style='letter-spacing:-.1pt'> </span>CI)<span style='letter-spacing:
     1.95pt'> </span>0.53<span style='letter-spacing:.05pt'> </span>(0.37,<span
     style='letter-spacing:-.05pt'> </span>0.74)<o:p></o:p></span></p>
     <p class=MsoNormal style='margin-right:.9pt;line-height:115%;tab-stops:
     123.45pt'><span style='font-size:8.0pt;mso-bidi-font-size:11.0pt;
     line-height:115%'>KM<span style='letter-spacing:-.05pt'> </span>median:<span
     style='letter-spacing:-.05pt'> </span>POM+LD-DEX=NE<span style='mso-tab-count:
     1'>     </span>[48.1,<span style='letter-spacing:.05pt'> </span>NE]<span
     style='letter-spacing:.05pt'> </span>KM median: HD-DEX<span
     style='mso-spacerun:yes'>   </span>=<span style='mso-spacerun:yes'>  
     </span>34.0[23.4, 39.9]<span style='letter-spacing:.05pt'> </span>Events:<span
     style='letter-spacing:-.2pt'> </span>POM+LD-DEX=75/284<span
     style='letter-spacing:-.3pt'> </span>HD-DEX=56/139<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="576" height="289" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image007.gif" />1.0</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.8</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1035"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:68.75pt;margin-top:.75pt;width:12pt;height:78.15pt;z-index:15733760;
 mso-position-horizontal-relative:page' filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
  inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:.6pt;margin-right:0in;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt'><span style='font-size:9.0pt;
    mso-bidi-font-size:11.0pt'>Propotion<span style='letter-spacing:-.15pt'> </span>of<span
    style='letter-spacing:-.1pt'> </span>Patients<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="20" height="108" alt="Text Box: Propotion of Patients" src="file:///C:/Users/AbdullahSAlanazi/AppData/Local/Packages/oice_16_974fa576_32c1d314_1292/AC/Temp/msohtmlclip1/01/clip_image005.gif" />0.6</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.4</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0.2</p><p>&nbsp;</p><p>&nbsp;</p><p>0.0</p><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65</p><p>&nbsp;</p><p>Overall Survival (week)</p><p>&nbsp;</p><p>cutoff: 07 Sep 2012</p><p><u>&nbsp;Paediatric population</u></p><p>In a Phase 1 single-arm, open-label, dose escalation study, the maximum tolerated dose (MTD) and/or recommended Phase2 dose (RP2D) of pomalidomide in paediatric patients was determined to be 2.6 mg/m<sup>2</sup>/day administered orally on Day 1 to Day 21 of a repeated 28-day cycle.</p><p>Efficacy was not demonstrated in a Phase 2 multi-centre, open-label, parallel-group study conducted in 52 pomalidomide-treated paediatric patients, aged 4 to 18 years with recurrent or progressive high- grade glioma, medulloblastoma, ependymoma or diffuse intrinsic pontine glioma (DIPG) with primary</p><p>&nbsp;</p><p>location in the central nervous system (CNS).</p><p>In the Phase 2 study, two patients in the high-grade glioma group (N=19) achieved a response as defined by protocol; one of these patients achieved a partial response (PR) and the other patient achieved a long term stable disease (SD), which resulted in an objective response (OR) and long-term SD rate of 10.5% (95% CI: 1.3, 33.1). One patient in the ependymoma group (N=9) achieved a long- term SD which resulted in an OR and long-term SD rate of 11.1% (95% CI: 0.3, 48.2). No confirmed OR or long-term SD was observed in any of the evaluable patients in either the diffuse intrinsic pontine</p><p>glioma (DIPG) group (N=9) or medulloblastoma group (N=9). None of the 4 parallel groups assessed in this Phase 2 study met the primary endpoint of objective response or long-term stable disease rate.</p><p>The overall safety profile of pomalidomide in paediatric patients was consistent with the known safety profile in adults. Pharmacokinetic (PK) parameters were evaluated in an Integrated PK Analysis of the Phase 1 and Phase 2 studies and were found to have no significant difference to those observed in adult patients (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Pomalidomide is absorbed with a maximum plasma concentration (C<sub>max</sub>) occurring between 2 and 3 hours and is at least 73% absorbed following administration of single oral dose. The systemic exposure (AUC) of pomalidomide increases in an approximately linear and dose proportional manner. Following multiple doses, pomalidomide has an accumulation ratio of 27 to 31% on AUC.</p><p>Coadministration with a high-fat and high-calorie meal slows the rate of absorption, decreasing mean plasma C<sub>max </sub>by approximately 27%, but has minimal effect on the overall extent of absorption with an 8% decrease in mean AUC. Therefore, pomalidomide can be administered without regard to food intake.</p><p>Distribution</p><p>Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state. Pomalidomide is distributed in semen of healthy subjects at a concentration of approximately 67% of plasma level at 4 hours post-dose (approximately T<sub>max</sub>) after 4 days of once daily dosing at 2 mg. <em>In vitro </em>binding of pomalidomide enantiomers to proteins in human plasma ranges from 12% to 44% and is not concentration dependent.</p><p>Biotransformation</p><p>Pomalidomide is the major circulating component (approximately 70% of plasma radioactivity) <em>in vivo </em>in healthy subjects who received a single oral dose of [<sup>14</sup>C]-pomalidomide (2 mg). No metabolites were present at &gt;10% relative to parent or total radioactivity in plasma.</p><p>The predominant metabolic pathways of excreted radioactivity are hydroxylation with subsequent glucuronidation, or hydrolysis. <em>In vitro</em>, CYP1A2 and CYP3A4 were identified as the primary enzymes involved in the CYP-mediated hydroxylation of pomalidomide, with additional minor contributions from CYP2C19 and CYP2D6. Pomalidomide is also a substrate of P-glycoprotein <em>in vitro</em>. Co-administration of pomalidomide with the strong CYP3A4/5 and P-gp inhibitor ketoconazole, or the strong CYP3A4/5 inducer carbamazepine, had no clinically relevant effect on exposure to pomalidomide. Co-administration of the strong CYP1A2 inhibitor fluvoxamine with pomalidomide in the presence of ketoconazole, increased mean exposure to pomalidomide by 107% with a 90% confidence interval [91% to 124%] compared to pomalidomide plus ketoconazole. In a second study to evaluate the contribution of a CYP1A2 inhibitor alone to metabolism changes, co-administration of fluvoxamine alone with pomalidomide increased mean exposure to pomalidomide by 125% with a 90% confidence interval [98% to 157%] compared to pomalidomide alone. If strong inhibitors of CYP1A2 (e.g. ciprofloxacin, enoxacin and fluvoxamine) are co-administered with pomalidomide, reduce the dose of pomalidomide to 50%. Administration of pomalidomide in smokers, with smoking tobacco known to induce the CYP1A2 isoform, had no clinically relevant effect on exposure to pomalidomide compared to that exposure to pomalidomide observed in non-smokers.</p><p>Based on <em>in vitro </em>data, pomalidomide is not an inhibitor or inducer of cytochrome P-450 isoenzymes, and does not inhibit any drug transporters that were studied. Clinically relevant drug-drug interactions are not anticipated when pomalidomide is coadministered with substrates of these pathways.</p><p>Elimination</p><p>Pomalidomide is eliminated with a median plasma half-life of approximately 9.5 hours in healthy subjects and approximately 7.5 hours in patients with multiple myeloma. Pomalidomide has a mean total body clearance (CL/F) of approximately 7-10 L/hr.</p><p>Following a single oral administration of [<sup>14</sup>C] -pomalidomide (2 mg) to healthy subjects, approximately</p><p>73% and 15% of the radioactive dose was eliminated in urine and faeces, respectively, with approximately 2% and 8% of the dosed radiocarbon eliminated as pomalidomide in urine and faeces.</p><p>Pomalidomide is extensively metabolised prior to excretion, with the resulting metabolites eliminated primarily in the urine. The 3 predominant metabolites in urine (formed via hydrolysis or hydroxylation with subsequent glucuronidation) account for approximately 23%, 17%, and 12%, respectively, of the dose in the urine.</p><p>CYP dependent metabolites account for approximately 43% of the total excreted radioactivity, while nonCYP dependent hydrolytic metabolites account for 25%, and excretion of unchanged pomalidomide accounted for 10% (2% in urine and 8% in faeces).</p><p>Population Pharmacokinetics (PK)</p><p>Based on population PK analysis using a two-compartment model, healthy subjects and MM patients had comparable apparent clearance (CL/F) and apparent central volume of distribution (V<sub>2</sub>/F). In peripheral tissues, pomalidomide was preferentially taken up by tumors with apparent peripheral distribution clearance (Q/F) and apparent peripheral volume of distribution (V<sub>3</sub>/F) 3.7-fold and 8-fold higher, respectively, than that of healthy subjects.</p><p><u>Paediatric population</u></p><p>Following a single oral dose of pomalidomide in<br />children and young adults with recurrent or<br />progressive primary brain tumour, the median<br />Tmax was 2 to 4 hours post-dose and<br />corresponded to geometric mean Cmax (CV%)<br />values of 74.8 (59.4%), 79.2 (51.7%), and 104<br />(18.3%) ng/mL at the 1.9, 2.6, and 3.4 mg/m2<br />dose levels, respectively. AUC0-24 and AUC0-inf<br />followed similar trends, with total exposure in<br />the range of approximately 700 to 800 h&middot;ng/mL<br />at the lower 2 doses, and approximately 1200<br />h&middot;ng/mL at the high dose. Estimates of half-life<br />were in the range of approximately 5 to 7<br />hours. There were no clear trends attributable<br />to stratification by age and steroid use at the<br />MTD.<br />Overall, data suggest that AUC increased nearly<br />proportional to the increase in pomalidomide<br />dose, while the increase in Cmax was generally<br />less than proportional.<br />The pharmacokinetics of pomalidomide following<br />oral administration dose levels of 1.9 mg/m2/day<br />to<br />3.4 mg/m2/day were determined in 70 patients<br />with ages from 4 to 20 years in an integrated<br />analysis of a Phase 1 and Phase 2 study in<br />recurrent or progressive paediatric brain<br />tumours. Pomalidomide concentration-time<br />profiles were adequately described with a one<br />compartment PK model with first- order<br />absorption and elimination. Pomalidomide<br />exhibited linear and time-invariant PK with<br />moderate variability. The typical values of CL/F,</p><p>Vc/F, Ka, lag time of pomalidomide were 3.94<br />L/h, 43.0 L,<br />1.45 h-1 and 0.454 h respectively. The terminal<br />elimination half-life of pomalidomide was 7.33<br />hours. Except for body surface area (BSA),<br />none of the tested covariates including age and<br />sex had effect on pomalidomide PK. Although<br />BSA was identified as a statistically significant<br />covariate of pomalidomide CL/F and Vc/F, the<br />impact of BSA on exposure parameters was not<br />deemed clinically relevant.<br />In general, there is no significant difference of<br />pomalidomide PK between children and adult<br />patients.</p><p>Elderly</p><p>Based on population pharmacokinetic analyses in healthy subjects and multiple myeloma patients, no significant influence of age (19-83 years) on oral clearance of pomalidomide was observed. In clinical studies, no dose adjustment was required in elderly (&gt; 65 years) patients exposed to pomalidomide (see section 4.2).</p><p>Renal impairment</p><p>Population pharmacokinetic analyses showed that the pomalidomide pharmacokinetic parameters were not remarkably affected in renally impaired patients (defined by creatinine clearance or estimated glomerular filtration rate [eGFR]) compared to patients with normal renal function</p><p>(CrCl &ge;60 mL/minute). Mean normalised AUC exposure to pomalidomide was 98.2% with a</p><p>90% confidence interval [77.4% to 120.6%] in moderate renal impairment patients (eGFR &ge;30 to &le;45 mL/minute/1.73 m2) compared to patients with normal renal function. Mean normalised AUC exposure to pomalidomide was 100.2% with a 90% confidence interval [79.7% to 127.0%] in severe renal impairment patients not requiring dialysis (CrCl &lt;30 or eGFR &lt;30 mL/minute/1.73 m2) compared to patients with normal renal function. Mean normalised AUC exposure to pomalidomide increased by 35.8% with a 90% CI [7.5% to 70.0%] in severe renal impairment patients requiring dialysis (CrCl &lt;30mL/minute requiring dialysis) compared to patients with normal renal function. The mean changes in exposure to pomalidomide in each of these renal impairment groups are not of a magnitude that requires dosage adjustments.</p><p>Hepatic impairment</p><p>The pharmacokinetic parameters were modestly changed in hepatically impaired patients (defined by Child-Pugh criteria) compared to healthy subjects. Mean exposure to pomalidomide increased by 51% with a 90% confidence interval [9% to 110%] in mildly hepatically impaired patients compared to healthy subjects. Mean exposure to pomalidomide increased by 58% with a 90% confidence interval [13% to 119%] in moderately hepatically impaired patients compared to healthy subjects. Mean exposure to pomalidomide increased by 72% with a 90% confidence interval [24% to 138%] in severely hepatically impaired patients compared to healthy subjects. The mean increases in exposure to pomalidomide in each of these impairment groups are not of a magnitude for which adjustments in schedule or dose are required (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeat-dose toxicology studies</p><p>In rats, chronic administration of pomalidomide at doses of 50, 250, and 1000 mg/kg/day for 6 months was well tolerated. No adverse findings were noted up to 1000 mg/kg/day (175-fold exposure ratio relative to a 4 mg clinical dose).</p><p>In monkeys, pomalidomide was evaluated in repeat-dose studies of up to 9 months in duration. In these studies, monkeys exhibited greater sensitivity to pomalidomide effects than rats. The primary toxicities observed in monkeys were associated with the haematopoietic/lymphoreticular systems. In the 9-month study in monkeys with doses of 0.05, 0.1, and 1 mg/kg/day, morbidity and early euthanasia of 6 animals were observed at the dose of 1 mg/kg/day and were attributed to immunosuppressive effects (staphylococcal infection, decreased peripheral blood lymphocytes, chronic inflammation of the large intestine, histologic lymphoid depletion, and hypocellularity of bone marrow) at high exposures of pomalidomide (15-fold exposure ratio relative to a 4 mg clinical dose). These immunosuppressive effects resulted in early euthanasia of 4 monkeys due to poor health condition (watery stool, inappetence, reduced food intake, and weight loss); histopathologic evaluation of these animals showed chronic inflammation of the large intestine and villous atrophy of the small intestine. Staphylococcal infection was observed in 4 monkeys; 3 of these animals responded to antibiotic treatment and 1 died without treatment. In addition, findings consistent with acute myelogenous leukemia led to euthanasia of 1 monkey; clinical observations and clinical pathology and/or bone marrow alterations observed in this animal were consistent with immunosuppression. Minimal or mild bile duct proliferation with associated increases in ALP and GGT were also observed at 1 mg/kg/day. Evaluation of recovery animals indicated that all treatment-related findings were reversible after 8 weeks of dosing cessation, except for proliferation of intrahepatic bile ducts observed in 1 animal in the 1 mg/kg/day group. The No Observed Adverse Effect Level (NOAEL) was 0.1 mg/kg/day (0.5-fold exposure ratio relative to a 4 mg clinical dose).</p><p>Genotoxicity/carcinogenicity</p><p>Pomalidomide was not mutagenic in bacterial and mammalian mutation assays, and did not induce chromosomal aberrations in human peripheral blood lymphocytes or micronuclei formation in polychromatic erythrocytes in bone marrow of rats administered doses up to 2000 mg/kg/day. Carcinogenicity studies have not been conducted.</p><p>Fertility and early embryonic development</p><p>In a fertility and early embryonic development study in rats, pomalidomide was administered to males and females at dosages of 25, 250, and 1000 mg/kg/day. Uterine examination on Gestation Day 13 showed a decrease in mean number of viable embryos and an increase in postimplantation loss at all dosage levels. Therefore, the NOAEL for these observed effects was &lt; 25 mg/kg/day (AUC <sub>24h </sub>was 39960 ng&bull;h/mL (nanogram&bull;hour/millilitres) at this lowest dose tested, and the exposure ratio was 99-fold relative to a 4 mg clinical dose). When treated males on this study were mated with untreated females, all uterine parameters were comparable to the controls. Based on these results, the observed effects were attributed to the treatment of females.</p><p>Embryo-foetal development</p><p>Pomalidomide was found to be teratogenic in both rats and rabbits when administered during the period of major organogenesis. In the rat embryofoetal developmental toxicity study, malformations of absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (central and/or neural arches) were observed at all dosage levels (25, 250, and 1000 mg/kg/day).</p><p>There was no maternal toxicity observed in this study. Therefore, the maternal NOAEL was</p><p>1000 mg/kg/day, and the NOAEL for developmental toxicity was &lt; 25 mg/kg/day (AUC<sub>24h </sub>was 34340 ng&bull;h/mL on Gestation Day 17 at this lowest dose tested, and the exposure ratio was 85-fold relative to a 4 mg clinical dose). In rabbits, pomalidomide at dosages ranging from 10 to 250 mg/kg produced embryo-foetal developmental malforma tions. Increased cardiac anomalies were seen at all doses with significant increases at 250 mg/kg/day. At 100 and 250 mg/kg/day, there were slight increases in post-implantation loss and slight decreases in fetal body weights. At 250 mg/kg/day, fetal malformations included limb anomalies (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia); moderate dilation of the lateral ventricle in the brain; abnormal placement of the right subclavian artery; absent intermediate lobe in the lungs; low-set kidney; altered liver morphology; incompletely or not ossified pelvis; an increased average for supernumerary thoracic ribs and a reduced average for ossified tarsals. Slight reduction in maternal body weight gain, significant reduction in triglycerides, and significant decrease in absolute and relative spleen weights were observed at 100 and 250 mg/kg/day. The maternal NOAEL was 10 mg/kg/day, and the developmental NOAEL was &lt;10 mg/kg/day (AUC<sub>24h </sub>was 418 ng&bull;h/mL on</p><p>Gestation Day 19 at this lowest dose tested, which was similar to that obtained from a 4 mg clinical dose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsule contents</p><p>Mannitol (E421)</p><p>Starch, pregelatinised</p><p>Sodium stearyl fumarate</p><p>Capsule shell</p><p>Imnovid 1 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172) White and black ink</p><p>Imnovid 2 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172)</p><p>Erythrosin (E127)</p><p>White ink</p><p>Imnovid 3 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Yellow iron oxide (E172) White ink</p><p>Imnovid 4 mg hard capsules Gelatin</p><p>Titanium dioxide (E171)</p><p>Indigotine (E132)</p><p>Brilliant blue FCF (E133)</p><p>White ink</p><p>Printing ink</p><p><em><u>Imnovid 1 mg hard capsules</u></em></p><p>White ink</p><p>Shellac</p><p>Titanium dioxide (E171)</p><p>Simeticone</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p><p>Black ink</p><p>Shellac</p><p>Iron oxide black (E172)</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p><p><em><u>Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules</u></em></p><p>White ink</p><p>Shellac</p><p>Titanium dioxide (E171)</p><p>Simeticone</p><p>Propylene glycol (E1520)</p><p>Ammonium hydroxide (E527)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>o</sup>C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The capsules are packaged in Polyvinyl chloride (PVC)/ polychlorotrifluoroethylene (PCTFE) blisters with push through aluminium foil.</p><p>Pack size of 21 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened or crushed. If powder from pomalidomide makes contact with the skin, the skin should be washed immediately and thoroughly with soap and water. If pomalidomide makes contact with the mucous membranes, they should be thoroughly flushed with water.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Unused medicinal product should be returned to the pharmacist at the end of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>